

CURRICULUM VITAE

RODICA BUSUI (POP-BUSUI) M.D., Ph.D.

Professor,
Department of Internal Medicine
Division of Metabolism, Endocrinology and Diabetes
Co-Director, Neuropathy Center,
University of Michigan
5329 Brehm Tower for Diabetes Research
1000 Wall Street, Ann Arbor, MI 48105
734-647-9809
rpbusui@umich.edu

EDUCATION	2
POST DOCTORAL TRAINING	2
CERTIFICATIONS/LICENSURES	2
ACADEMIC APPOINTMENTS	3
GRANT SUPPORT	4
CURRENT	4
COMPLETED	6
HONORS AND AWARDS	10
MEMBERSHIP IN PROFESSIONAL SOCIETIES	10
EDITORIAL POSITIONS, BOARDS AND PEER-REVIEW SERVICE	11
TEACHING ACTIVITIES	12
GRAND ROUNDS PRESENTATIONS	Error! Bookmark not defined.
COMMITTEE, ORGANIZATIONAL AND VOLUNTEER SERVICE	15
CONSULTING POSITIONS	16
EXTRAMURAL INVITED PRESENTATIONS	16
SPECIAL/INVITED PRESENTATIONS AT NATIONAL/INTERNATIONAL MEETINGS	20
BIBLIOGRAPHY	30
PUBLICATIONS – PEER REVIEWED	30
BOOKS AUTHORED/CHAPTER IN BOOKS	32
ABSTRACTS	34

RODICA BUSUI (POP-BUSUI)
Professor
1000 Wall Street, 5329 Brehm Tower
734-647-9809
rpbusui@umich.edu

EDUCATION AND TRAINING

- 09/76-06/81 College of Mathematics-Physics, Resita, Romania
B.S. in Mathematics-Physics. Graduated Summa cum laude
- 09/81-09/87 University of Timisoara School of Medicine, Timisoara, Romania
M.D. Graduated Summa cum laude
- 9/95-11/01 University of Timisoara, School of Medicine, Timisoara, Romania
Ph.D. in Molecular Biology. Graduated Summa cum laude, Dissertation title:”
“Oxidative Stress and Diabetic Neuropathy”, advisor Professor Gheorghe S.
Bacanu M.D., Ph.D.

POST DOCTORAL TRAINING

- 11/87-9/90 Internship in General Medicine, University Hospital, Timisoara, Romania
- 9/90-12/93 Resident in Internal Medicine, Department of Internal Medicine at University
Hospital, Timisoara, Romania
- 04/94-07/94 Visiting research fellow, Internal Medicine, Royal Hallamshire Hospital,
Sheffield, UK
- 9/95-8/98 Research fellow, Department of Internal Medicine, Division of Endocrinology
and Metabolism, University of Michigan Medical Center, Ann Arbor, MI
- 9/98-8/01 Clinical fellow, Department of Internal Medicine, Division of Endocrinology and
Metabolism, University of Michigan Medical Center, Ann Arbor, MI

CERTIFICATIONS/LICENSURES

- 10/1987 General Medicine, Board Certified in Romania
- 02/1994 Internal Medicine, Board Certified in Romania
- 03/1998 ECFMG Educational Commission for Foreign Medical Graduates (certified)
- 03/2001 American Association for Clinical Endocrinology, Accreditation in Thyroid
Ultrasound

- 07/2001 USMLE, Final licensure examination
Michigan Medical License since 1998, Expires 01/31/2017
Ohio Medical License since 2001, Expires 07/01/2014
- 08/2012 American Board of Internal Medicine, Board Certified
- 10/2013 American Board of Endocrinology, Metabolism and Diabetes, Board Certified
- 04/2014 Diabetes Technology Society, Certified Diabetes Technology Clinician

ACADEMIC, ADMINISTRATIVE, AND CLINICAL APPOINTMENTS

- 09/90-11/97 Assistant Professor of Internal Medicine, University of Timisoara, School of Medicine, Department of Internal Medicine, Division of Diabetes, Nutrition and Metabolic Disorders, Timisoara, Romania
- 10/01-06/05 Assistant Professor of Medicine and Physiology, Instructional Track, Division of Endocrinology and Metabolism, University of Toledo Medical Center (former Medical College of Ohio), Toledo, OH
- 03/04-06/05 Faculty member of the Graduate School at the University of Toledo Medical Center, Toledo, OH
- 07/03-06/05 Director Diabetes Education Program at the University of Toledo Medical Center, Toledo, OH
- 07/05-08/11 Assistant Professor of Internal Medicine, Instructional Track, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes (MEND), University of Michigan Medical School, Ann Arbor, MI
- 09/11-08/15 Associate Professor with tenure of Internal Medicine, Instructional Track, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes (MEND), University of Michigan Medical School, Ann Arbor, MI
- 11/05- Co-Director, Neuropathy Center, University of Michigan Medical Center, Ann Arbor, MI
- 09/15- Professor of Internal Medicine with tenure, Instructional Track, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes (MEND), University of Michigan Medical School, Ann Arbor, MI

CLINICAL/HOSPITAL APPOINTMENTS

- 11/1987-06/90 Internship in General Medicine, University Hospital No 1, Timisoara, Romania

- 09/90-12/93 Resident Physician, Internal Medicine, University Hospital No 1, Timisoara, Romania
- 12/93-11/97 Attending physician Department of Internal Medicine, University Hospital No 1, Timisoara, Romania
- 10/01-6/05 Attending physician, Department of Medicine, University of Toledo Medical Center, Toledo, OH
- 07/05- Attending physician, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
- 07/05- Attending physician, Hyperglycemia Intensive Insulin Program, University of Michigan, Ann Arbor, MI

RESEARCH INTERESTS

Dr. Pop-Busui's research interests extend from the elucidation of the mechanisms underlying the development of diabetes and prediabetes' complications, with particular emphasis on diabetic cardiovascular autonomic and peripheral neuropathy, to the design and execution of clinical trials to test these mechanisms and to test novel therapies for preventing these complications in patients with type 1 and type 2 diabetes.

GRANT SUPPORT

CURRENT

NIH/NHLBI-1R01HL102334-01: Cardiac Autonomic Neuropathy and Myocardial Dysfunction in Type 1 Diabetes.

PI: Pop-Busui, 30% effort/year,

5/1/10-4/30/16

Total Direct Costs: \$1,537,479

NIH/NIDDK1U01 DK0945157-01: The Epidemiology of Diabetes Interventions and Complications

Subcontract Case Western Reserve

7/1/11-6/30/16

Herman (PI), Pop-Busui (co-Investigator) 5% effort/year

Total Award: \$1,018,819

The aims of this study is to evaluate the development and progression of microvascular complications in patients with type 1 diabetes as part of a multi-center longitudinal observational study of the Diabetes Control and Complications Trial (DCCT) cohort who are participating in the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

NIH/NIDDK 1DP3DK094292 Tissue-Specific Metabolic Reprogramming in Diabetic Complications

Brosius (PI), Pop-Busui (co-I; PI clinical trial) 10% effort/ year,

9/30/11-8/31/16

Total Award \$ 3,546,488

The major goal of this project is to apply sensitive and specific mass spectrometer based metabolomic analysis in models of diabetes to define changes in metabolite levels and flux in three complications-prone tissues, retina, kidney and peripheral nerves and to extend these studies to humans with T1DM to understand intrinsic differences from non-diabetics in metabolite levels and flux in the kidney.

NIH/NIDDK 1 UC4 DK101108 PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D

9/30/13-11/30/18

Pop-Busui (site PI, member Steering Committee), 20% effort/year Total Award \$ 2, 074.554

The major goal of this project is to examine the effectiveness of allopurinol to prevent GFR loss in patients with type 1 diabetes.

NIH/NIDDK (CDC Contract #200-2010-35171): Surveillance, Natural History, Quality of Care and Outcomes of Diabetes Mellitus with Onset in Childhood and Adolescence (SEARCH).

Feldman (PI), Pop-Busui (Co-I), Pop-Busui, 3% effort/year,

10/1/10-8/30/15

Annual Direct Costs: \$33,785

The major goals of this project are: to monitor the onset of diabetic autonomic and peripheral neuropathy in children

NIH/NIDDK U01-DK-098246: The Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study

Subcontract George Washington University

1/1/13-1/31/17

Herman (PI), Pop-Busui (PI), 10% effort/year

Total Award: \$205,928 for

1/1/13-7/31/13

The goal of this study is to compare the metabolic effects of four common anti-hyperglycemic drugs when combined with metformin and assess the time to treatment failure defined as HbA1c $\geq 7\%$, subsequently confirmed, after having been treated with metformin and a second randomly assigned antihyperglycemic medication, in a randomized clinical trial in patients with recent-onset type 2 diabetes.

American Diabetes Association 1-14-MN-02: Impact of glycemic variability on cardiovascular autonomic neuropathy and cardiomyopathy in type 1 diabetes.

Mentor-Based Postdoctoral Fellowship

2/1/14-1/31/16

Pop-Busui (PI)

Total Direct Costs \$127,747

This a mentor-based postdoctoral fellowship aiming to provide a strong clinical translational research experience for a postdoctoral fellow, under the mentorship of Dr Pop-Busui and develop quantitative analyses of continuous glucose monitoring (CGM) data and test whether persistent, wide blood glucose fluctuations, defined with newly-developed, sensitive metrics of GV predict the development of chronic T1DM complications focusing on cardiovascular complications.

University of Michigan Clinical Scholar Award: 7/2005, Total Direct Costs: \$ 200,000

**Astra Zeneca /AMYLIN PHARMACEUTICAL : Investigator initiated research
“Exenatide and Diabetic Neuropathy”.**

PI: Pop-Busui

6/08-12/15

Total Direct Costs: \$544,646

NIH/NIMH- 2-R01-MH-082784-06A1: Antipsychotic and Folate Pharmacogenomics

Ellingrod (PI), Pop-Busui (Co-I), 5% effort/year,

7/22/13-6/30/18

Total Direct Costs: \$1,250,000

The goal of this study is to examine folate pharmacogenomics in relation to metabolic syndrome, insulin resistance, and endothelial dysfunction from atypical antipsychotic use in schizophrenia and to determine the utility of folate supplementation in attenuation of these complications.

NIH/NHLBI-1R01HL113029-01A1 (Subcontract from University of Colorado)

Complications and Comorbidities of Type 1 Diabetes (CACTI)

Snell-Bergeon (PI), Pop-Busui (Co-I), 3% effort/year

6/1/13-5/31/18

Total Direct Costs: \$205,000

The goal of this study is to study the development and progression of subclinical coronary atherosclerosis in type 1 diabetes and identify noninvasive measurements to identify those patients at high risk.

Novo Nordisk: Devote (EX1250-4080)

Pop-Busui (site PI, member of trial leadership team)

7/13/14-6/30/19

Total Direct Costs: \$490,560.

A multicenter, randomized, double blind, placebo-controlled cardiovascular outcomes trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events

Juvenile Diabetes Research Foundation 17-2013-504 (Subcontract from Yale)

Pop-Busui site PI

7/1/14-6/30/16

Total Direct Costs \$ 77,013

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon) on Glucose Control in Patients with Type I Diabetes.

NIH DK-13-027 Multinational Collaborative Evaluation of Corneal Confocal Microscopy as a Surrogate Endpoint for the Identification and Prediction of Diabetic Neuropathy in Type 1 Diabetes

Perkins (University of Toronto), Pop-Busui (Co-I)

1/2015-12/2017

Annual Direct \$ 41,332

The major goals of this project are to determine if corneal confocal microscopy is a sensitive endpoint for diabetic neuropathy

Helmsley Trust Foundation/ T1D Exchange: Adjunctive versus Replacement Continuous Glucose Monitoring (CGM) RCT

Pop-Busui (site PI, CC Jaeb Center)

3/2015-12/2016

Annual Direct \$ 155,639

The major goals of this project are to evaluate whether the routine use of CGM without blood glucose meter (BGM) confirmation is as safe and effective as CGM used as an adjunct to BGM.

**Juvenile Diabetes Research Foundation Residual C Peptide in Type 1 Diabetes
N019726 354256**

Pop-Busui PI Clinical Trial University of Michigan

09/2014-12/2016

The major goals of this project are to evaluate beta-cell function and other immune markers in patients with long-standing type 1 diabetes

COMPLETED

NIH/NIDDK1 R34 DK097808-01: A multicenter clinical trial of allopurinol to prevent GFR loss in T1D (PERL)

Subcontract from Joslin Diabetes Center

12/1/12-12/31/13

(Doria, Joslin Diabetes Ctr PI), Pop-Busui site PI

Total Award: \$ 49,645.00

The major goal of this project is to design a multicenter clinical trial to tests the efficacy of allopurinol as compared to placebo, in preventing diabetic nephropathy among subjects with Type 1 Diabetes

Hoffmann-La Roche: ALECARDIO BC22140 - A multicenter, randomized, double blind, placebo-controlled cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus.

Site PI: Pop-Busui,

1/1/11-1/10/13

Total Direct Costs: \$250,000

NIH/NIMH-1R01MH082784-01: Folate Pharmacogenomics and Risk of Atypical Antipsychotic Metabolic Side Effects.

PI: Ellingrod, Co-Investigator: Pop-Busui, 5% effort/year

4/1/08-7/31/13

Total Direct Costs: \$1,250,000

NIH/NIDDK 1R03 DK094499-01: Targeting Inflammation using Salsalate in Type 1 Diabetic Neuropathy (TINSAL-T1DN)

The major goal of this project is to design a multicenter clinical trial to tests the efficacy of salsalate as compared to placebo, in preventing diabetic neuropathy among subjects with T1D.

PI: Pop-Busui, 7% effort,

9/15/11-8/31/12

Total Direct Costs: \$ 50,000

NIH/NIDDK 1R03 DK094484-01 PERL consortium

Pop-Busui (Co-I), Dorria Joslin Diabetes Center (PI)

10/1/11-11/30/12

The major goal of this project is to design a multicenter clinical trial to test the efficacy of allopurinol as compared to placebo, in preventing diabetic nephropathy among subjects with Type 1 Diabetes.

NIH/NIDDK/N01-DK-6-2203: Epidemiology of Diabetes Intervention and Complications.

PI: Herman, Co-Investigator: Pop-Busui, 5% effort/year, 3/1/00–6/30/11, Total Direct Costs: \$1,098,810

NIH/NIDDK: TINSAL-T2D (Targeting Inflammation using SALsalate for Type 2 Diabetes Stage 2) a multicenter trial.

Site PI: Pop-Busui, 3% effort, 5/1/09-7/31/11, Total Direct Costs: \$89,760

JUVENILE DIABETES RESEARCH FOUNDATION: Diffusion Tensor Imaging (DTI) of Sural Nerves in Diabetic Peripheral Neuropathy.

PI: Pop-Busui, 15% effort/year, 9/1/08-8/31/12, Total Direct Costs: \$675,000

Eli Lilly and Company: H9X-MC-GBCF-A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once Weekly Subcutaneous LY2189265 compared to Sitagliptin in Patients with Type 2 Diabetes Mellitus

Site PI: Pop-Busui, 8/08-8/12, 2 % effort Total Direct Costs: \$128,551

AMERICAN DIABETES ASSOCIATION-1-08-CR-48: Molecular Mechanisms of Cardiac Autonomic Neuropathy in Metabolic Syndrome.

PI: Pop-Busui, 20% effort/year, 1/1/08-6/30/11, Total Direct Costs: \$600,000

Pilot and Feasibility Grant from the Michigan Diabetes Research and Training Center NIH Grant 5P60-DK020572.

PI: Pop-Busui, 12/08-12/10, Total Direct Costs: \$50,000

NIH/NHLBI - NO1HC95181: Action to Control Cardiovascular Risk in Diabetes (ACCORD).

Site PI for University of Toledo site: Pop- Busui until 09/30/05, 30 % effort, Co-Investigator 7/1/05-6/30/10, 12/01-06/10, Total Direct Costs for site \$3,650,356

NIH/NHLBI/NIDDK-Case Western Reserve: ACCORD-EYE sub-Study.

Site PI for University of Toledo site: Pop-Busui until 09/30/05, Co-Investigator as of 07/01/05-6/30/10, Total Direct Costs: \$125/visit/patient

NIH/NHLBI Case Western Reserve: ACCORD-MIND–Study.

Site PI for University of Toledo site: Pop-Busui until 06/30/05, Co-Investigator as of 07/01/05-6/30/10, Total Direct Costs: \$150/visit/patient

JUVENILE DIABETES RESEARCH FOUNDATION: Oxidative Stress and Cardiac Denervation.

PI: Feldman, Co-Investigator: Pop-Busui, 10% effort, 7/1/05-12/31/09, Total Direct Costs: \$2,965,778

NIH/NHLBI F007546: Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI-2D) study.

Diabetes PI for the University of Michigan site: Pop-Busui, 3% effort, 7/1/05-9/30/09; Total Direct Costs: \$157,547

NIH/NIDDK/NCT00006305: NeuroEDIC (The Epidemiology of Diabetes Interventions and Complications (EDIC) Neuropathy).

Co-Investigator: Pop-Busui, 10% effort, 7/1/05-9/30/09, Total Direct Costs: 397,004

NIH/NINDS: R-21 Cyclooxygenase Pathway and Diabetic Neuropathy.

PI: Pop-Busui, 20% effort, 1/04-5/07, Total Direct Costs: \$ 250,000

Eli Lilly and Company: H9X-MC-GBCJ- The Effect of Dose Titration of LY2189265 (GLP-1 analog IV-Fc) in Overweight and Obese Patients with Type 2 Diabetes Mellitus (The EGO Study).

Site PI: Pop-Busui, 10% effort, 3/1/08-8/31/10, Total direct costs: \$ 473,613.00

Novartis: CLAF 237A24138- A Multi Center, Randomized, Double Blind, Active Controlled Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment with Vildagliptin (50mg qd or 100 mg qd or 100 mg qd) Versus Sitagliptin (25 mg qd) in Patients with Type 2 Diabetes and Severe Renal Disease

Site PI: Pop-Busui, 2/08-7/09, Total Direct Costs \$114, 877.

Eli Lilly and Company: H7U-MC-IDBA -A Phase 3, Open-Label, Three-Group Parallel Study to Assess the Efficacy of Inhaled Insulin in Patients with Type 2 Diabetes.

Site PI: Pop-Busui, 5% effort, 7/06-12/08, Total Direct Costs: \$192,651

GlaxoSmithKline: A Feasibility Research Study to Assess Diabetic Control and Treatment Regimens in Patients with Type 2 Diabetes Mellitus.

Site PI: Pop-Busui, 1% effort, 6/06-8/06, Total Direct Costs: \$3,000

MITSUBISHI Pharma Inc. A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20 mg, 40 mg and 80 mg of MCC-257 in Patients with Mild to Moderate Diabetic Polyneuropathy.

PI: Feldman, Co-Investigator: Pop-Busui, 2/06-1/08

Eli Lilly and Company: The Global Hypopituitary Control and Complications Study (HypoCCS- 9 years global observational research study.

Site PI University of Toledo: Pop-Busui, 3% effort, 3/1/04-6/31/05, Total Direct Costs: \$21,330

GlaxoSmithKline: Effect of Rosiglitazone on Endothelial Dysfunction Complicating Diabetes.

PI: Stevens, Co-Investigator: Pop-Busui, 5/1/01-12/30/2007

Sanofi-Aventis: “Evaluation of diabetic retinopathy progression in subjects with type 2 diabetes mellitus treated with insulin”.

PI: Stevens, Co-Investigator: Pop-Busui, 1998-1999

ASTA Medica AG “Dose-Finding Trial on the Antidiabetic Properties of Dexamipotam in Patients with Type 2 Diabetes Mellitus.

PI: Stevens, Co-Investigator: Pop-Busui, 1998-2000

ASTA Medica AG: Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy.

PI: Stevens, Co-Investigator: Pop-Busui, 5/1/98-12/31/02

HONORS AND AWARDS

- | | |
|-----------|--|
| 1982 | University of Timisoara School of Medicine, Award in Anatomy |
| 1983 | University of Timisoara School of Medicine, Award in Physiology |
| 1985 | University of Timisoara School of Medicine, Honorary Award in Internal Medicine |
| 1995 | Fulbright Award |
| 2001 | American Diabetes Association Endocrinology Fellow of Excellence Award |
| 2002 | Honorary Lectureship Brazilian Diabetes Association Annual Meeting, Porto Alegre, Brazil |
| 2003 | Honorary Lectureship Romanian Diabetes Association Annual Meeting, Bucharest, Romania |
| 2004 | Honorary lectureship Department of Diabetes and Cardiovascular Diseases, Bad Oeyhausen, Germany |
| 2005 | University of Michigan Clinical Science Scholar Award |
| 2011 | University of Michigan League of Research Excellence Award |
| 2013-2015 | American Diabetes Association’s Clinical Practice Committee |
| 2013 | Honorary Member Romanian Society of Diabetes, Nutrition and Metabolic Diseases |
| 2014 | Diabetes Honoris Causa awarded by the Romanian Society of Diabetes, Nutrition and Metabolic Diseases |
| 2014 | Honorary Member of the NEURODIAB - Society for Diabetic Neuropathy |

MEMBERSHIP IN PROFESSIONAL SOCIETIES

International Societies:

- | | |
|--------------|---|
| 1995-present | American Diabetes Association |
| 1998-present | Endocrine Society |
| 1999-present | American Association of Clinical Endocrinologists |
| 2001-present | American Medical Association |
| 2003-present | American Heart Association |
| 1993-present | European Association for the Study of Diabetes (EASD) |
| 1998-present | Neuropathy Study Group of the EASD (NEURODIAB) |

1993-1994 European Association for the Study of Obesity
1990-1995 Balcanic Medical Association
2014-present NEURODIAB - Society for Diabetic Neuropathy

National Societies:

1990-present Romanian Diabetic Association
1990-2000 Romanian Association of Internal Medicine
1994-2008 Romanian Association for the Study of Childhood Diabetes
2013- Romanian Society of Diabetes, Nutrition & Metabolic Diseases

Local Societies:

1996-present Michigan Affiliate of American Diabetes Association
2011-present Cardiovascular Center at the University of Michigan

EDITORIAL POSITIONS, BOARDS AND PEER-REVIEW SERVICE

Editorial Boards:

2006-present Member of the Editorial Board of Experimental Diabetes Research
2006-present Member of the Editorial Board of Review of Endocrinology
2012-present Member of the Editorial Board of Diabetes and Its Complications
2012-present Member of the Editorial Board of Frontiers in Diabetes
2012-present Member of the Editorial Board of Frontiers in Endocrinology
2014-present Member of the Editorial Board and Section Editor of Current Diabetes Reports

Associate Editor

2014-present Member of the Editorial Board and Section Editor of Current Diabetes Reports
2015-present Section Editor, Current Diabetes Reports
2015-present Associate Editor, Journal of Diabetes and its Complications

Study Sections:

2004-2005 Member of the Peer Review Committees of the American Heart Association
2008 Member of the July 2008 Peer Review Committees of the Juvenile Diabetes Research Foundation – Study section – complications
2008 Member of the Special Peer Review Committees on diabetes complications of the Juvenile Diabetes Research Foundation
2010-2013 Member of the Complications Therapies Strategic Research Committee of the Juvenile Diabetes Research Foundation
2010 Member of the University of Michigan Peer-Review Committee on the Peking University Clinical Research Program as part of the University of Michigan and Peking University Research Initiative.
2012-2014 American Diabetes Association’s Scientific Sessions Meeting Planning Committee
2013-2015 American Diabetes Association’s Clinical Practice Committee
2013 Member of the JDRF Evaluation Committee of REMOVAL Clinical Trial

- 2013 Member of the NIH ZDK1 GRB-J J3 Study Section-Special Emphasis Panel for the NIDDK Multi-Center Clinical Study Implementation Planning Grants (U34)
- 2014-present Member of the American Diabetes Association (ADA) Research Grant Review Committee (RGRC)
- 2014 Member of the NIH ZDK1GRB-S (O2) NIDDK Study Section -Special Emphasis Panel NIDDK
- 2014 Member of the JDRF Canadian Clinical Trial Network (CCTN) Post-Doctoral Fellowships in Clinical Translation in Type 1 Diabetes Grant Review

Ad-Hoc Journal Reviewer:

- 2004 Reviewer for manuscripts for the “Antioxidant& Redox Signaling”
- 2005-present Reviewer for Diabetes/Metabolism/Research/Review
- 2006-present Reviewer for the Diabetes Metabolism Clinical Practice
- 2007-present Reviewer for Journal of Clinical Endocrinology and Metabolism
- 2007-present Reviewer for Journal of the Peripheral Nervous System
- 2008 Reviewer for the Journal of Nutrition, Metabolism & Cardiovascular Diseases
- 2010-present Reviewer for Diabetic Medicine
- 2011 Reviewer for the Journal of Autonomic Nervous System
- 2011-2012 Reviewer for Diabetes Technology and Therapeutics
- 2011-present Reviewer for Diabetes Care
- 2012 Reviewer for Diabetes and Its Complications
- 2012-present Reviewer for the Journal of American College of Cardiology
- 2013 Reviewer for Annals of Internal Medicine
- 2014 Reviewer for JAMA
- 2014-present Reviewer BMJ

TEACHING ACTIVITIES

- 1990-1995 Assisted in teaching as an Assistant Professor in Internal Medicine, Department of Internal Medicine, University of Timisoara Medical School, Timisoara, Romania
- 1998-2001 Assisted in teaching as an Endocrine fellow at the University of Michigan Hospitals, Department of Internal Medicine, Division of Endocrinology and Metabolism, Ann Arbor, MI
- 09/99–06/01 Clinical skills instructor-University of Michigan Medical School, Ann Arbor, MI
- 10/01-06/05 Teaching in the Medical School and Graduate School at the University of Toledo (former Medical College of Ohio), Toledo, OH:

Lectures at the Monthly Department of Medicine Endocrine Conference
 Attended by students, residents, 50-75 attendees per session.
 Topics covered: Diabetic neuropathies, Pituitary tumors, Renin-Angiotensin-Aldosterone system, Congenital adrenal hyperplasia

Lectures at the junior clerkship endocrine rotation – two lectures quarterly
Attended by M3 students, 40 attendees per session- Diabetes mellitus

Lectures at the Introduction to the patient teaching sessions as part of the organ block system M2 students: Covered adrenal insufficiency, diabetes mellitus and Graves' disease

Core Curriculum Lectures: Diabetic Ketoacidosis; July 2002, 2003, 2004

Course Director, University of Toledo Annual Diabetes Symposium

1. Broad Horizons in the Management of Type 2 Diabetes. CME Symposium, October 19, 2002
2. Treating To Goal and Beyond: Closing the Gap between Inpatient-Outpatient Diabetes Management. CME Symposium, January 30, 2004

Lectures given at these symposiums: “Impact of insulin therapy on cardiovascular risk in type 2 diabetes.” “Role of Intensive Insulin Treatment in Inpatient Setting”

Attending physician: Inpatient endocrine consultation service

7 months a year from October 2001 to February 2003, daily from March 2003 to September 2004, every other month from September 2004-June 2005.

Attending physician teaching: medicine residents in endocrine ambulatory rotation

Student rotations: 3rd and 4th year medical student rotation on outpatient endocrine clinic

Mentoring 2 graduate students in my lab and supervised 3 undergraduate students during the summer undergraduate research program at the University of Toledo

Faculty at the Internal Medicine Board Review Course University of Toledo

June 21, 2002 Update in Endocrinology

June 17, 2003 Update in Endocrinology

07/2005-present Teaching in the Medical School at the University of Michigan, Ann Arbor, MI:

Attending physician teaching: endocrine fellows and internal medicine residents in endocrine inpatient and ambulatory rotations-ongoing

Mentor graduate student Aaron Kellogg, Program Molecular Basis of Disease in my lab who followed me from the University of Toledo and has graduated June 2008 from the Molecular Basis of Disease Program at the

University of Toledo

Student rotations: 3rd and 4th year medical student rotation on outpatient endocrine clinic - ongoing

Mentor Summer Internship-graduate student from School of Public Health, Renuka Coehlo, Summer 2006

Mentor UROP student Fall 2006

Small Group Endocrine Teaching 2008

Mentor: Endocrine fellow- Dr. Sima Saberi 2007 - 2009

Mentor: Summer Biomedical Research Program 2009 : M2 student - Laurel E. Roberts, class 2012

Co-Mentor with Dr Saran Sanjiv: Nephrology fellow- Dr. Preeti Chandra 2008 - 2010

Mentor: Endocrine fellow - Dr. Leena Jha 2009 - 2011

Epid 552, Chronic Disease Epidemiology, lecture on diabetes complications 12/09, School of Public Health

Small Group Endocrine Teaching 2010

Mentor: Summer Biomedical Research Program 2010, M2 Student Mitali Mehta, class 2013

Mentor: UROP student Rajsekhar Kadiyala, 2011 - 2012

Mentor: Graduate student Katherine McKeon, M. Engineering in Pharmaceutical Engineering 2012

Mentor: Summer Biomedical Research Program 2012 : M2 Elizabeth White, Oakland University

Mentor: Postdoctoral fellow Mamta Jaiswal, 2012-ongoing

Mentor: UROP student Jacqueline Albosta, 2012 – 2013

Mentor: Summer Biomedical Research Program 2013: Ashley Shinke, M2 University of Michigan

Mentor: Endocrine fellow – Dr. Lynn Ang, 2013-2015

Mentor: Summer Biomedical Research Program 2014: Nicole Nevarez ,
M2 University of Michigan

Course Director: University of Michigan CME Annual Course “Diabetes and
Endocrinology Updates”, 2008-2013, which was transitioned into the Diabetes
Update Course as of 2014.

Co-Chair: Brehm Tower 5th Anniversary Symposium, November 6th 2015

COMMITTEE, ORGANIZATIONAL AND VOLUNTEER SERVICE

National

1998-present	Member of the Diabetes Complications Council of the American Diabetes Association
2004-2008	Member of the Council for Clinical Research of the American Association of Clinical Endocrinologists
2008, 2012, 2013, 2014, 2016	Abstract reviewer for the American Diabetes Association Annual Meetings
2011-present	Member, DCCT/EDIC Adherence Monitoring Committee
2013-2014	Member, American Diabetes Association Annual Scientific Meeting Committee
2013-2015	Member, American Diabetes Association Professional Practice Committee
2015-	Co-chair DCCT/EDIC Research Committee

International

2015-2016	Chairmen Elect of the 2016 Neuropathy Study Group of the EASD Annual Meeting
-----------	--

University of Michigan

2006-2007	Member, Future of Diabetes Care at the University of Michigan
2007-present	Member, Briarwood 2 MEND Clinical Committee
2007	Co-Director of the Endocrinology & Diabetes Update CME Course
2008-present	Director of the Endocrinology & Diabetes Update CME Course
2009-present	In charge of the MEND Research Conference with Drs. Bernal-Mizrachi and Oral
2010	Member, MEND Faculty Retreat Committee
2010	Member, University of Michigan Peer Review Committee for the Peking University Clinical Research Program on the Perspective epidemiology study of obstructive sleep apnea and progression of diabetic retinopathy
2010-present	Member, Division of MEND Search Committee
2010	Member, Deployment Team for the UMHS Strategic Planning Process to implement improvements in clinical research
2011-2012	Member, MiChart Research Physicians Champions Committee

2011-2012	Member, Medical School CME Committee
2012-	Member, Department of Internal Medicine's Promotions Committee
2012	Member, MSTP Career Advisory Panel
2013	Member, Michigan Institute for Clinical & Health Research (MCTO)
2013	Member, MiChart Research Leadership Team
2013-present	Member, Research BPA Committee
2014-2015	Member, Michigan Comprehensive Diabetes Center Operational Committee

University of Toledo Committees

2001-2005	Transplant Committee
2002-2005	Admissions Committee Medical School
2004	Search Committee for the Department of Neurosciences Chair
2004-2005	Admission Committee Graduate School
2004-2005	Member of the Medical College of Ohio President Advisory Council for Research
2004-2005	Member of the Research Advisory Committee for the Office of Inter Universities Research Collaboration of Ohio

Volunteer Service

2009	Educational lectures for the Amputees Support Group of Ann Arbor and the Juvenile Diabetes Research Foundation patient support meetings
2012	Educational Lecture for the University of Michigan Diabetes Students Support Group
2011-present	Juvenile Diabetes Research Foundation
2012-present	American Diabetes Association

CONSULTING POSITIONS

2004-2009	Occasional consultant for Pfizer Pharmaceutical Inc. and Sanofi-Aventis
2011	Occasional consultant for Amylin Pharmaceuticals
2013	Occasional consultant for Jansen Pharmaceutical
2014	Occasional consultant for Astra Zeneca

VISITING PROFESSORSHIPS, SEMINARS, AND EXTRAMURAL INVITED PRESENTATIONS

GRAND ROUNDS PRESENTATIONS

1. Diabetes mellitus; Family Practice Grand Rounds, St. Vincent's, Toledo, OH, November 2001
Managing type 2 Diabetes; Medicine Grand Rounds, Flower Hospital, Toledo, OH, April 2002
2. New Concepts in Diabetic Neuropathies – From Glucotoxicity to Oxidative Stress and Beyond; Department of Medicine Grand Rounds University of Toledo, September 2002

3. New Concepts in Diabetic Neuropathies. Department of Pathology Grand Rounds, Wayne State University, November 2002
4. An Update in Diabetic Neuropathies: clinical and pathophysiological considerations. Endocrinology Grand Rounds, Wayne State University, May 2004
5. A Challenge for the 21st Century: the Deadly Quartet in Metabolic Syndrome and Type 2 Diabetes. Medicine Grand Rounds, University of Toledo, October 21, 2004
6. Diabetic Neuropathies. Endocrinology Grand Rounds, Case Western Reserve University, November 2004
7. An Update in the Management of Diabetes, Internal Medicine Grand Rounds, McLaren Medical Center, Flint, MI, October 2008
8. Cardiac Autonomic Neuropathy in Diabetes and Prediabetes, Citywide Endocrine Rounds at the University of Toronto, September 25, 2009
9. Can We Cure Diabetic Neuropathy? Role of Risk Factor Control, Medical Grand Rounds, University of Michigan Health System, January 2012
10. Risk Factor Control and Diabetic Neuropathy. Grand Rounds at the Joslin Diabetes Center, Boston, May 2012
11. Can We Cure Diabetic Neuropathy? Role of Risk Factor Control, Citywide Endocrine Rounds at the University of Toronto, May 18 2012
12. Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in Diabetes. Frontiers in Cardiovascular Science seminar series, The University of Michigan Cardiovascular Center (CVC), November 2012
13. Cardiovascular Autonomic Neuropathy in Diabetes. Grand Rounds Presentation, Department of Internal Medicine, Korea University, Seoul, Korea, March 8, 2013.
14. Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in Diabetes. Grand Rounds Presentation, Department of Internal Medicine, University of Utah, Salt Lake City, July 2013.
15. Diagnosis and Management of Diabetic Neuropathy. MSMS Foundation 3rd Annual Spring Scientific Meeting, The Henry, Dearborn, MI, May 2014.
16. Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes. Grand Rounds Presentation, Department of Internal Medicine, University of Iowa, Iowa City, September, 2015.

17. Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes. Invited Plenary Lecture at the University of Chicago Diabetes Day, May 2015, Chicago , IL

INTERNAL TALKS

1. Nerve taurine replacement attenuates oxidative stress, nerve blood flow and conduction deficits in streptozotocin-diabetic rats. 5th Annual Research Day Scientific Session, Department of Internal Medicine, University of Michigan, February 1997
2. Regulation of taurine transporter in diabetes. Research Conference, Division of Endocrinology and Metabolism, University of Michigan, March 1998
3. Dysregulation of taurine transporter in diabetes. Research Conference, Division of Endocrinology and Metabolism, University of Michigan, March 1999
4. Down-regulation of sciatic nerve Na⁺-taurine co-transporter in streptozotocin-diabetic rats – a potential mediator of glucose-toxicity. Seventh Annual Department of Internal Medicine Research Day, University of Michigan, May 1999
5. COX pathway and diabetic neuropathy. Research Conference, Division of Endocrinology and Metabolism, University of Michigan, October 5, 2000
6. Diabetes Mellitus. CME presentation at the University of Michigan Kellogg Eye Center 80th Annual Spring Conference, Ann Arbor, MI, May 30, 2008
7. Intensive Insulin treatment. CME presentation at the University of Michigan 2008 Annual Endocrinology & Diabetes CME Update Course, The Inn at St. Johns, Plymouth, MI, October 2008
8. The Glucose-Cardiovascular Disease Connection – the Search for the Missing Link. **Invited Plenary Talk** at the Michigan Diabetes Research and Training Center Winter Symposium, 2009
9. The Link between Glucose and Cardiovascular Disease in Type 2 Diabetes. Plenary Talk at the Annual Endocrinology & Diabetes CME Update Course, The Inn at St. Johns, Plymouth, MI, October 2009
10. Sympathetic Activation and Myocardial Dysfunction in Type 1 Diabetes, Division of MEND Research Conference, January 2010
11. Effects of Multiple Risk Factor Management on Micro and Macrovascular Outcomes in the ACCORD Trial, Division of MEND Clinical Conference, August 2010
12. Risk Factor Management and Micro and Macrovascular Outcomes in the ACCORD Trial. Plenary Talk at the Annual Endocrinology & Diabetes Update CME Course, The Inn at St. Johns, Plymouth, MI, October 2010

13. Cardiovascular Autonomic Neuropathy and Myocardial Dysfunction in Diabetes. **Invited Plenary Talk** at the Diabetes Complications Research Symposium organized jointly by the University of Michigan Diabetes Comprehensive Diabetes Center, the Michigan Diabetes Research and Training Center, Michigan Metabolomics and Obesity Center and the Michigan Institute for Clinical and Health Research (MICHR), Ann Arbor MI, November 2010
14. What is New in Diabetes Diagnosis and Treatment. Plenary Talk at the Annual Endocrinology & Diabetes Update CME Course, Eagle Crest, Ypsilanti, MI, October 2011
15. Diabetes- Year in Review. Plenary Talk at the Annual Endocrinology & Diabetes Update CME Course, The Inn at St. Johns, Plymouth, October 2012
16. Update in Diabetic Neuropathy: Teaching Conference for the Endocrine Fellows, MEND Division, October 2012
17. Clinical Research Tips in Diabetes and Related Disorders-Study Design, Outcomes, Methods to assess beta-cell function and insulin sensitivity, Teaching Conference for the Endocrine Fellows, MEND Division, August 2013.
18. New and Not so New Ideas in Optimizing Treatment in Type 2 Diabetes. Lecture at the University of Michigan' "Advancing Outpatient Diabetes Care" CME Course, The Inn at St. Johns, Plymouth, April, 2014.
19. Update in Diabetic Neuropathy: Teaching Conference for the Endocrine Fellows, MEND Division, November 2014.
20. Update on Diabetes Complications. Plenary Talk at the Annual Endocrinology & Diabetes Update CME Course, The Inn at St. Johns, Plymouth, April, 2015.
21. Planning and Conduction of Clinical Trials: Pitfalls and Necessary Considerations. Teaching Conference for the Endocrine Fellows, MEND Division, August 2015.

REGIONAL AND EXTRAMURAL TALKS

1. Peripheral diabetic neuropathy. Toledo area diabetes educators. AADE, March 12, 2002
2. Managing type 2 diabetes. Monroe Medical Society CME Conference, March 13, 2002
3. Broad Horizons in the Management of Type 2 Diabetes. "Impact of insulin therapy on cardio-vascular risk in type 2 diabetes." University of Toledo Annual Endocrinology CME Symposium, October 19, 2002

4. Treating to Goal and Beyond: Closing the gap between Inpatient-Outpatient Management of Diabetes. “Role of Intensive Insulin Treatment in Inpatient Setting”. University of Toledo Annual Endocrinology CME Symposium, January 30, 2004
5. Maintaining Quality of Life in Patients with Schizophrenia: An Endocrine Point of View. CME Symposia series sponsored by the University of Florida, Tampa FL, St Louis, MI, Minneapolis, MN, June-Sept. 2004
6. An update on Diabetic Neuropathies. CME presentation sponsored by Florida Diabetes Prevention Center and University of Florida, May 2005
7. Diabetic Neuropathies. CME presentation sponsored by the University of Colorado, The Great Lakes Symposium on Metabolic Syndrome, Novi, MI, May 2006.
8. Update in Diabetic Neuropathies. CME presentation at Annual Meeting of The Great Lakes Association of Podiatry, February 2013, Troy, MI.
9. Optimize treatment of Diabetic Neuropathy and Overview of the GRADE Trial, Invited plenary lecture at the Endocrine Club-MI chapter of the American Association of Clinical Endocrinologists (AACE). September 2013.

SPECIAL/INVITED PRESENTATIONS AT NATIONAL/INTERNATIONAL MEETINGS

1. **Pop-Busui R**, Bacanu GH, Sporea I: Detection of early gastric emptying showing in patients with long-standing diabetes by ultrasonography. Romanian Diabetes Association Annual Meeting, Brasov, Romania, March 1994
2. **Pop-Busui R**, Bacanu GH, Sporea I: Effect of cisapride and erythromicine on gastric emptying in diabetic patients. Romanian Diabetic Association Annual Meeting, Bucharest, Romania, March 1995
3. **Pop-Busui R**, Van Huysen C, Beyer L, Towns R, Greene DA, Stevens, MJ: Dissociation of nerve blood flow and nerve conduction velocity by acetyl-L-carnitine treatment in streptozotocin diabetes. 56th American Diabetic Association’s Annual Meeting, San Francisco, CA, June 1996
4. **Pop-Busui R**: Down-regulation of sciatic nerve Na⁺-taurine co-transporter in streptozotocin-diabetic rats – a potential mediator of glucose-toxicity. 8th NEURODIAB Meeting, Sitges, Spain, September 1998
5. **Pop-Busui R**: Down-regulation of sciatic nerve Na⁺-taurine co-transporter in streptozotocin-diabetic rats – a potential mediator of glucose-toxicity. 34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona, Spain, September 1998

6. **Pop-Busui R:** Myocardial endothelial dysfunction complicates sympathetic dysinnervation in diabetic autonomic neuropathy. 59th Annual Scientific Session of the American Diabetes Association, San Diego, CA, June 1999
7. **Pop-Busui R:** Metabolic, vascular and nerve conduction deficits induced by cyclooxygenase inhibition in experimental diabetes. 60th Annual Scientific Session of the American Diabetes Association, San Antonio, TX, June 2000
8. **Pop-Busui R:** A case of amiodarone induced thyrotoxicosis. 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 2000
9. **Pop-Busui R:** Taurine replacement prevents apoptosis in experimental diabetic neuropathy. Fifth Diabetic Neuropathy Satellite to the International Diabetes Federation Congress 2000, San Jose, Costa Rica, November 2000
10. **Pop-Busui R:** The Diabetic Foot. Professional Symposia of the Regional Association of the Outpatients Surgeons of Hestia, Frankfurt, Germany, February 2001
11. **Pop-Busui R, Marinescu V, Sullivan K, Larkin D, Li F, Stevens MJ:** Cyclooxygenase (COX)-2 expression is selectively increased in the sciatic nerve of streptozotocin diabetic (STZ-D) rats. 61st Annual Scientific Session of the American Diabetes Association, Philadelphia, PA, June 2001
12. **Pop-Busui R, Raffel D, Stevens MJ:** Oxidative Stress is associated with abnormal myocardial blood flow regulation in subjects with Type 1 diabetes and microangiopathy. 61st Annual Scientific Session of the American Diabetes Association, Philadelphia, PA, June 2001
13. **Pop-Busui R, Raffel D, Schroeder J, Stevens MJ:** C-reactive protein is associated with abnormal myocardial blood flow regulation in subjects with Type 1 Diabetes and Microangiopathy. 62nd Annual Scientific Session of the American Diabetes Association, San Francisco, CA, June 12, 2002
14. **Pop-Busui R, Raffel D, Schroeder J, Stevens MJ:** Oxidative stress adrenergic hyper-reactivity and endothelial dysfunction complicating Type 1 Diabetes. NEURODIAB Annual Meeting, Balaton-Fured, Hungary, August 30, 2002
15. **Pop-Busui R:** Cyclooxygenase pathway and peripheral diabetic neuropathy. Brazilian Diabetes Association Annual Meeting, Porto Alegre, Brazil, December 2002
16. **Pop-Busui R:** Protein kinase C and diabetes complications Brazilian Diabetes Association Annual Meeting, Porto Alegre, Brazil, December 2002
17. **Pop-Busui R, Kellogg AP, Li F, Larkin D, Stevens MJ:** Cox-2-Knock-Out Mice Are Protected from Nerve Conduction Velocity Slowing in Experimental Diabetes. 63rd American Diabetes Association Annual Meeting, New Orleans, June 2003

18. **Pop-Busui R**, Kellogg AP, Li F, Larkin D, Stevens MJ: Cox-2-Knock-Out Mice are Protected from Nerve Conduction Velocity Slowing in Experimental Diabetes. NEURODIAB Annual Meeting, Saint-Malo, France, August 2003
19. **Pop-Busui R**, Stevens MJ, Schroeder J, Raffel D: Adrenergic Hyper-Responsiveness and Paradoxical Myocardial Blood Flow Regulation Complicate Type 1 but Not Type 2 Diabetes Mellitus. NEURODIAB Annual Meeting, Saint-Malo, France, August 2003
20. **Pop-Busui R**: Effects of COX-2 Gene Inactivation on Nerve Conduction Velocity and Oxidative Stress in Experimental Diabetes. 64th American Diabetes Association Annual Meeting, Orlando, FL, June 2004
21. **Pop-Busui R**: An Update in Diabetic Neuropathies: From Glucotoxicity to Oxidative Stress and Beyond. Department of Diabetes and Cardiovascular Diseases Special Grand Round Presentation, Bad Oyehausen, Germany, September 1, 2004
22. **Pop-Busui R**: Effects of COX-2 Gene Inactivation on Nerve Conduction Velocity and Oxidative Stress in Experimental Diabetes II. Joint Meeting of NEURODIAB and Diabetic Foot Study Group of the EASD, Regensburg, Germany, September 3, 2004
23. **Pop-Busui R**: Cyclooxygenase (COX)-2 Selective Inhibition, Oxidative Stress and Inflammation in Experimental Diabetic Peripheral Neuropathy. 65th American Diabetes Association Annual Meeting, San Diego CA, June 2005
24. **Pop-Busui R**: Effects of Cyclooxygenase (COX) Inhibition on Nerve Conduction Velocity (NCV) and Sensory Fiber Function in Experimental Diabetes. 15th Annual Meeting of the NEURODIAB, Porto Heli Greece, September 2005
25. **Pop-Busui R**: Protective Effects of Cyclooxygenase-2 (COX-2) Gene Inactivation on Functional and Biochemical Deficits of Experimental Diabetic Neuropathy are Maintained after Longer Diabetes Duration. 15th Annual Meeting of the NEURODIAB, Porto Heli Greece, September 2005
26. **Pop-Busui R**: Effects of Cyclooxygenase-2 (COX-2) Gene Inactivation on Myocardial Oxidative Stress and Inflammation in Experimental Diabetes. American Heart Association Scientific Session, Dallas, 2005
27. **Pop-Busui R.:** Long Term Protective Effects of Cyclooxygenase-2 (COX-2) Gene Inactivation on Functional Deficits of Experimental Diabetic Neuropathy. 66th American Diabetes Association Annual Meeting, Washington DC, June 2006
28. **Pop-Busui R**: Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial. 16th Annual Meeting of the NEURODIAB, Ystad, Sweden, September 2006

29. **Pop-Busui R:** Cross Talk between Cyclooxygenase-2 (COX-2) pathway, oxidative stress and inflammation in long term experimental diabetic neuropathy. 16th Annual Meeting of the NEURODIAB, Ystad, Sweden, September 2006
30. **Pop-Busui R,** Kellogg AP, Hayes J, Larkin D, Stevens MJ, Feldman EL: Protective effects of cyclooxygenase-2 (cox-2) gene inactivation against intraepidermal nerve fibers loss and peripheral nerve dysfunction in long-term experimental diabetes. 7th International Symposium of Diabetic Neuropathy of the International Diabetes Federation, Cape Town, South Africa, November-December 2006.
31. **Pop-Busui R: Invited Plenary Key Note Address :** Cutting Edge Theories on the Pathogenesis of Diabetic Neuropathies, 7th International Symposium of Diabetic Neuropathy of the International Diabetes Federation, Cape Town, South Africa, November-December 2006
32. **Pop-Busui R:** Prevalence of Diabetic Peripheral Neuropathy (DPN) and Relation to Glycemic Control Strategies at Baseline in the BARI 2D Cohorts. Oral presentation at the 67th American Diabetes Association Annual Meeting, Chicago IL, June 2007
33. **Pop-Busui R:** Rosiglitazone Ameliorates Nitrosative Stress and Inflammation in Type 2 Diabetes. Poster presentation at the 67th American Diabetes Association Annual Meeting, Chicago IL, June 2007
34. **Pop-Busui R:** Rosiglitazone Ameliorates Nitrosative Stress and Preserves Myocardial Blood Flow in Type 2 Diabetes. Oral presentation at the 17th Annual Meeting of the NEURODIAB, Utrecht, The Netherlands, September 2007
35. **Pop-Busui R:** Cardiac Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Oral presentation at the 68th American Diabetes Association Annual Meeting, San Francisco, CA, June 2008
36. **Pop-Busui R:** Cardiac Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Oral presentation at the 18th Annual Meeting of the NEURODIAB, Orvieto, Italy, September 2008
37. **Pop-Busui R:** Cardiac Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Oral presentation at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD), Rome Italy, September 2008
38. **Pop-Busui R: Invited plenary presentation:** Clinical Initiatives in Cardiovascular Disease in Diabetes. The renal week - Annual Meeting of the American Society of Nephrology, Philadelphia, November 2008

39. **Pop-Busui R**, Raffel D, Byun J, Rubenfire M, Giri A, Ryan K, Brown M, Pennathur S: Oxidative Stress and Cardiovascular Denervation in Subjects with Metabolic Syndrome. Presentation at the 3rd International Congress of Prediabetes and Metabolic Syndrome
40. **Pop-Busui R**, Raffel D, Byun J, Rubenfire M, Giri A, Ryan K, Brown M, Pennathur S: Cardiovascular Denervation and Oxidative Stress in Subjects with Metabolic Syndrome. Oral presentation at the 69th American Diabetes Association Annual Meeting, New Orleans, LA, June 2009
41. **Pop-Busui R**, Evans G, Gerstein H, Fonseca V, Hoogwerf B, Genuth S, Fleg J, Grimm R, Corson M, Prineas R, and the ACCORD Study Group. Cardiac Autonomic Dysfunction Predicts Cardiovascular Mortality in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Oral presentation at the 69th American Diabetes Association Annual Meeting, New Orleans, LA, June 2009
42. **Pop-Busui R**: **Platform Invited Presentation** Cardiac Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). The Annual Meeting of the Peripheral Nerve Society, Wurzburg, Germany, July 2009
43. **Pop-Busui R**: **Oral Invited Presentation**: Cardiovascular Denervation and Oxidative Stress in Subjects with Metabolic Syndrome. The joint session of the 8th International Symposium on Diabetic Neuropathy and 19th Annual Meeting of the Diabetic Neuropathy Study Group of the EASD- NEURODIAB, Toronto, Canada, October 2009
44. **Pop-Busui R**: **Oral Invited Presentation**: Association between Hypoglycemia and Impaired Cardiovascular Autonomic Function in the DCCT/EDIC cohort. The joint session of the 8th International Symposium on Diabetic Neuropathy and 19th Annual Meeting of the Diabetic Neuropathy Study Group of the EASD- NEURODIAB, Toronto, Canada, October 2009
45. **Pop-Busui R**: **Oral Invited Presentation**: Cardiac Autonomic Neuropathy and Left Ventricular Function in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). The Annual Meeting of the American Heart Association, Orlando, Florida, November, 2009
46. **Pop-Busui R**: Validation of the Michigan Neuropathy Screening Instrument as a Measure of Distal Symmetrical Peripheral Neuropathy in Type 1 Diabetes: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). The 70th American Diabetes Association Annual Meeting, Orlando, FL, June 2010.
47. **Pop-Busui R**: Pathogenesis of Diabetic Neuropathy. **Invited plenary Lecture at the 8th National Congress of the Romanian Federation of Diabetes, Nutrition and Metabolic Diseases**. Cluj-Napoca, Romania, September 9, 2010.

48. **Pop-Busui R:** “Diabetic Neuropathy before and after DCCT-EDIC and ACCORD Trials” **Invited plenary Lecture at the 5-Th Central European Association for the Study of Diabetes Congress, Cluj-Napoca, Romania, September 10, 2010**
49. **Pop-Busui R: Invited Seminar Debate:** Assessing Cardiac Autonomic Neuropathy in Research and Clinical Care, The 20th Annual NEURODIAB Meeting, Stockholm, Sweden, September 2010
50. **Pop-Busui R:** Effects of Intensive Risk Factor Management on Measures of Neuropathy in Participants with Type 2 Diabetes enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial, the 20th Annual NEURODIAB Meeting, Stockholm, Sweden, September 2010
51. **Pop-Busui R:** Progression of Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC): oral presentation at the 71st Annual Meeting of the American Diabetes Association Meeting, June 2011, San Diego, CA.
52. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy, Oxidative Stress and Lifestyle Intervention in Subjects with Metabolic Syndrome: Audio tour presented poster at the 71st Annual Meeting of the American Diabetes Association Meeting, June 2011, San Diego, CA.
53. **Pop-Busui R:** Progression of Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC): oral presentation at the 21st Annual NEURODIAB Meeting, Porto, Portugal, September 2011.
54. **Pop-Busui R:** Risk Factor Control and Diabetic Neuropathy: Lessons from ACCORD. Invited Plenary Lecture at the Annual Meeting of the European Association for the Study of Diabetes (EASD), Lisbon, Portugal, September 2011.
55. **Pop-Busui R:** Intensive Risk Factor Control and Diabetic Complications. Invited Plenary Lecture at the Annual Meeting of the Brazilian Diabetes Association Meeting, Brasilia, Brazil, October 2011.
56. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy in Diabetes. Invited Plenary Lecture at the Annual Meeting of the Brazilian Diabetes Association Meeting, Brasilia, Brazil, October 2011.
57. **Pop-Busui R.** New Therapeutic Approach for Insulin Resistance and Inflammation. Invited Plenary Lecture at the Annual Meeting of the Brazilian Diabetes Association Meeting, Brasilia, Brazil, October 2011.
58. **Pop-Busui R:** Left Ventricle Function and Sympathetic Innervation in Type 1 Diabetes. American Heart Association Annual Meeting, Orlando Florida, November 2011.

59. **Pop-Busui R:** Impact of Glycemic Control Strategies on the Incidence of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort: Oral presentation at the 72nd Annual Meeting of the American Diabetes Association Meeting, Philadelphia, PA, June 2012.
60. **Pop-Busui R:** Autonomic Measurements and Cardiovascular Outcomes in Diabetes. Invited Plenary Lecture at the 72nd Annual Meeting of the American Diabetes Association Meeting, Philadelphia, PA, June 2012.
61. **Pop-Busui R:** Peripheral Neuropathy in the SEARCH for Diabetes in Youth Cohort: A Pilot Study: Audio tour presented poster at the 72nd Annual Meeting of the American Diabetes Association Meeting, Philadelphia, PA, June 2012.
62. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy in the SEARCH for Diabetes in Youth Cohort: A Pilot Study: Audio tour presented poster at the 72nd Annual Meeting of the American Diabetes Association Meeting, Philadelphia, PA, June 2012.
63. **Pop-Busui R:** Impact of Glycemic Control Strategies on the Incidence of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort: Oral presentation at the 22nd Annual Meeting of the Annual Meeting of the Diabetic Neuropathy Study Group (NEURODIAB), Dresden, Germany, September 2012.
64. **Pop-Busui R:** Peripheral Neuropathy in the SEARCH for Diabetes in Youth Cohort: A Pilot Study. Oral presentation at the 22nd Annual Meeting of the Annual Meeting of the Diabetic Neuropathy Study Group (NEURODIAB), Dresden, Germany, September 2012.
65. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy in the SEARCH for Diabetes in Youth Cohort: A Pilot Study: Audio tour presented poster at the 22nd Annual Meeting of the Annual Meeting of the Diabetic Neuropathy Study Group (NEURODIAB), Dresden, Germany, September 2012.
66. **Pop-Busui R:** In vivo confocal evaluation of the corneas in patients with diabetes mellitus. Tour presented poster at the 22nd Annual Meeting of the Annual Meeting of the Diabetic Neuropathy Study Group (NEURODIAB), Dresden, Germany, September 2012.
67. **Pop-Busui R:** Association between Impaired Cardiovascular Autonomic Function and Hypoglycemia in Patients with Type 1 Diabetes Mellitus. Presented Poster American Heart Association Annual Meeting, Los Angeles, CA, November 2012.
68. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy, Myocardial Dysfunction and Cardiovascular Outcomes. The 2nd Annual D. Dan and Betty Kahn University of Michigan-Technion University Collaborative Cardiovascular Research Symposium, Haifa, Israel, December 2012.
69. **Pop-Busui R:** Global Initiatives in Major Diabetes Clinical Trials. The 3rd Annual Meeting on Global Clinical Trials, Seoul, Korea, March 8, 2013.

70. **Pop-Busui R:** Clinical implications of cardiovascular autonomic neuropathy in diabetes. Invited plenary lecture; International symposium Past, Present and Future in Diabetes Complications Research, Bucharest Romania, May 2013.
71. **Pop-Busui R:** Can We Cure Diabetic Neuropathies? Clinical Endpoints and Lessons from Clinical Trials Invited Special Plenary Lecture at the 39th Annual Meeting of the Romanian Diabetes Society Meeting, May 2013, Sibiu, Romania.
72. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy and Erectile Dysfunction in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC): Oral presentation at the 73rd Annual Meeting of the American Diabetes Association Meeting, Chicago, IL, June 2013.
73. **Pop-Busui R:** Glycemic Variability but Not Glycemic Exposure Predicts Lower Heart Rate Variability in Patients with type 1 diabetes: Oral presentation at the 73rd Annual Meeting of the American Diabetes Association Meeting, Chicago, IL, June 2013.
74. **Pop-Busui R:** Identification of Factors Associated With Sural Nerve Regeneration and Degeneration in Diabetic Neuropathy. Audio tour presented poster at the 73rd Annual Meeting of the American Diabetes Association Meeting, Chicago, IL, June 2013.
75. **Pop-Busui R:** Autonomic Neuropathy from Diagnosis to Treatment. Plenary symposium at the Brazilian Endocrine Meeting, Recife, Brazil, June 2103.
76. **Pop-Busui R:** Peripheral Diabetic Neuropathy Treatment Update. Plenary symposium at the Brazilian Endocrine Meeting, Recife, Brazil, June 2103.
77. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy and Erectile Dysfunction in Men with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Oral presentation at the 23rd Annual Meeting of the Annual Meeting of the Diabetic Neuropathy Study Group (NEURODIAB), Barcelona, Spain, September 2013.
78. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy and Lower Urinary Tract Symptoms in Men with Type 1 Diabetes. Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain, September 2013.
79. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy from Diagnosis to Prognosis. State-of-the-Art lecture at the XIX Congress of the Brazilian Diabetes Society, Florianopolis, Brazil, October 2013.
80. **Pop-Busui R:** Metabolic Syndrome and Diabetic Complications. State-of-the-Art lecture at the XIX Congress of the Brazilian Diabetes Society, Florianopolis, Brazil, October 2013.

81. **Pop-Busui R:** Meet the Professors: Practical tips in diagnosis and treatment of autonomic neuropathies; at the XIX Congress of the Brazilian Diabetes Society, Florianopolis, Brazil, October 2013.
82. **Pop-Busui R:** Left Ventricular Metabolism, Function and Sympathetic Innervation in Type 1 Diabetes. The Annual Meeting of the American Heart Association, Los Angeles, CA, November 2013.
83. **Pop-Busui R:** Clinical Implications of the Autonomic Neuropathies. Invited Special Plenary Lecture at the 40th Annual Meeting of the Romanian Diabetes Society Meeting, May 2014, Sibiu, Romania.
84. **Pop-Busui R:** New Insights on Diabetic Nephropathy. Invited Special Plenary Lecture at the 40th Annual Meeting of the Romanian Diabetes Society Meeting, May 2014, Sibiu, Romania.
85. **Pop-Busui R:** Meet the Professors: How to Approach the Patient with Diabetic Neuropathy; at the 74th Annual Meeting of the American Diabetes Association Meeting, San Francisco, June 2014.
86. **Pop-Busui R:** Diabetic Neuropathy and Urologic Complications in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC); poster presentation at the 74th Annual Meeting of the American Diabetes Association Meeting, San Francisco, June 2014.
87. **Pop-Busui R:** Effects of Exenatide on Measures of Small Fiber Neuropathy in Patients with Type 2 Diabetes; poster presentation at the 74th Annual Meeting of the American Diabetes Association Meeting, San Francisco, June 2014.
88. **Pop-Busui R:** Prevalence and Risk Factors of Cardiovascular Autonomic Neuropathy among Youth with Type 1 Diabetes: SEARCH Cohort Study; Audio presented poster presentation at the 74th Annual Meeting of the American Diabetes Association Meeting, San Francisco, June 2014.
89. **Pop-Busui R:** Diabetic Neuropathy and Urologic Complications in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Oral presentation at the 24th Annual Diabetic Neuropathy Study Group (NEURODIAB) Meeting, September 2014, Sopron Hungary.
90. **Pop-Busui R:** Diabetic Neuropathy and Urologic Complications in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Oral presentation at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), September 2014, Vienna, Austria.
91. **Pop-Busui R:** Cardiac Autonomic Neuropathy in Type 1 Diabetes. NIH Workshop on Cardiovascular Disease and Type 1 Diabetes, October 2014, NIH campus Bethesda, MD.

92. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in Type 1 vs. Type 2 Diabetes- Lessons from Large Clinical Trials. Plenary Invited Lecture at the 2nd Congress in Diabetic Neuropathy and Diabetic Foot, Bucharest, Romania, October 2014.
93. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in Diabetes. Invited Plenary Lecture at the 2014 Cardiovascular Program Retreat of the Karolinska Institutet, Val Gard, Stockholm, Sweden, October 2014.
94. **Pop-Busui R:** Diabetes Getting on your Nerves. Plenary Invited Lecture at the 97th Annual Meeting of the Endocrine Society. March 2015, San Diego, CA.
95. **Pop-Busui R:** Burden of Diabetic Peripheral Neuropathy among Pima Indians; poster presentation at the 75th Annual Meeting of the American Diabetes Association Meeting, Boston , June 2015.
96. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy and Coronary Artery Calcium in Type 1 Diabetes: The CACTI Study; poster presentation at the 75th Annual Meeting of the American Diabetes Association Meeting, Boston; June 2015.
97. **Pop-Busui R:** Longitudinal Changes of Sudomotor Function in Type 1 Diabetes (T1D); poster presentation at the 75th Annual Meeting of the American Diabetes Association Meeting, Boston; June 2015.
98. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy in Pima Indians with Diabetic Kidney Disease (DKD); poster presentation at the 75th Annual Meeting of the American Diabetes Association Meeting, Boston; June 2015.
99. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy in Pima Indians with Diabetic Kidney Disease (DKD); Invited plenary presentation at the 25th Annual Diabetic Neuropathy Study Group (NEURODIAB) Meeting, September 2015, Elsinore, Denmark.
100. **Pop-Busui R:** Longitudinal Changes of Sudomotor Function in Type 1 Diabetes (T1D); poster presentation at the 25th Annual Diabetic Neuropathy Study Group (NEURODIAB) Meeting, September 2015, Elsinore, Denmark.
101. **Pop-Busui R:** Blood Pressure Variability in Subjects with Type 1 Diabetes (T1D); poster presentation at the 25th Annual Diabetic Neuropathy Study Group (NEURODIAB) Meeting, September 2015, Elsinore, Denmark.
102. **Pop-Busui R:** Cardiovascular Autonomic Neuropathy in Pima Indians with Diabetic Kidney Disease (DKD); Oral poster presentation at the 51th Annual Meeting of the European Association for the Study of Diabetes (EASD), September 2015, Stockholm, Sweden.

103. **Pop-Busui R:** Cardiovascular and Other Autonomic Neuropathy in Diabetes- Clinical Pearls and Diagnostic Challenges. Plenary Invited Lecture at the 3rd Congress in Diabetic Neuropathy and Diabetic Foot, Bucharest, Romania, October 2015.
104. **Pop-Busui R:** How to Treat the Pain Due to Diabetic Neuropathy: Facts and Controversies. Plenary Invited Lecture at the Annual Meeting of the Diabetes Technology Society. Bethesda, October , 2015.

PATENTS

Submitted Fall 2011:

File #4984 “Tools for Making Informed Decisions on the Management of Patient Insulin”

BIBLIOGRAPHY

PUBLICATIONS – PEER REVIEWED

1. **Pop-Busui R,** Bacanu GH. Postural hypotension --a simple tool in detection of diabetic autonomic neuropathy. Timisoara Medicala. 1991, 3: 12-16.
2. Bacanu GH, Serban V, **Pop-Busui R,** Negrisanu G, Bordos D. The diabetic foot. Acta Diabetica Romania. 1993, 21:47.
3. Sporea I, **Pop-Busui R,** Goldis A. Ultrasonographic assessment of gastric emptying in patients with diabetic autonomic neuropathy. Romanian Journal of Gastroenterology. 1994, 8:121-123.
4. Bacanu GH, **Pop-Busui R,** Serban V, Timar R. Arterial hypertension and diabetes mellitus. Romanian Revue of Modern Medicine. 1996, 9: 7-13.
5. **Pop-Busui R,** Chey W, Stevens MJ. Severe Hypertension Induced by the Long-Acting Somatostatin Analogue Sandostatin LAR in a Patient with Diabetic Autonomic Neuropathy. Journal of Clinical Endocrinology & Metabolism. 2000, 85(3):943-946.
6. **Pop-Busui R,** Sullivan K, Van Huysen C, Bayer L, Beyer L, Cao X, Towns R, Stevens MJ. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular and functional deficits. Experimental Neurology. 2001, 168(2):259-72.
7. **Pop-Busui R,** Marinescu V, Van Huysen C, Li F, Sullivan K, Greene DA, Larkin D, Stevens MJ. Dissection of Metabolic, Vascular and Nerve Conduction Interrelationships in Experimental Diabetic Neuropathy by Cyclooxygenase Inhibition and Acetyl-L-Carnitine Administration. Diabetes. 2002, 51: 2619-2628.
8. **Pop-Busui R,** Kirkwood I, Schmid H, Marinescu V, Schroeder J, Larkin D, Raffel D, Stevens MJ. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. Journal of the American College of Cardiology. 2004, 44 (12): 2368-2374.

9. Kellogg AP, **Pop-Busui R**: Peripheral nerve dysfunction in Experimental Diabetes is mediated by Cyclooxygenase-2 and Oxidative Stress. Antioxidants & Redox Signaling. 2005, 7 (11-12): 1521-1529.
10. Nakashima E, **Pop-Busui R**, Towns R, Thomas TP, Hosaka Y, Nakamura J, Greene DA, Killen P, Schroeder J, Larkin D, Lam Ho Y, Stevens MJ. Regulation of the Human Taurine Transporter by Oxidative Stress in Retinal Pigment Epithelial Cells Stably Transformed to Overexpress Aldose Reductase. Antioxidants & Redox Signaling. 2005, 7 (11-12): 1530-1542.
11. **Pop-Busui R**, Sima AA, Stevens MJ. Diabetic Neuropathy and Oxidative Stress. Review. Diabetes, Metabolism, Research and Reviews. 2006, 22: 257–273.
12. **Pop-Busui R**: Lamotrigine for Treatment of Pain Associated with Diabetic Neuropathy: Results of Two Randomized, Double-Blind, Placebo-Controlled Studies. Nature Clinical Practice-Neurology. 2007, 3 (8): 424-425.
13. Albers JW, Herman WH, **Pop-Busui R**, Martin CL, Cleary P, Waberski B: Subclinical Neuropathy among Diabetes Control and Complications Trial Participants without Neuropathy at Trial End. Possible Predictors of Incident Neuropathy. Diabetes Care. 2007, 30(10):2613-16.
14. Kellogg AP, Wiggin T, Larkin D, Hayes J, Stevens MJ **and Pop-Busui R**: Protective Effects of Cyclooxygenase-2 Gene Inactivation against Peripheral Nerve Dysfunction and Intraepidermal Nerve Fibers Loss in Experimental Diabetes. Diabetes. 2007, 56 (12):2997-3005.
15. Kellogg AP, Cheng HT **and Pop-Busui R**: Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy. Current Drug Targets. 2008, 9(1):68-76.
16. Heung M **and Pop-Busui R**: Multidisciplinary Approach to the Management of Diabetes Complications. Review of Endocrinology. 2007, Vol 1, No 5, 30-34.
17. Field MG, Elnor VM, Puro DG, Feuerman J, Musch DC, **Pop-Busui R**, Hackel R, Heckenlively JR, Petty HR: Rapid, Non-invasive Detection of Diabetes-Induced Ocular Metabolic Stress. Archives of Ophthalmology. 2008, 126 (7):1-5.
18. Khanderia U, **Pop-Busui R**, Eagle K: Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective. Annals of Pharmacotherapy. 2008, 42 (10):1466-74.
19. **Pop-Busui R**, Lu J, Lopes N, Jones TL: Prevalence of Diabetic Peripheral Neuropathy and Relation to Glycemic Control Strategies at Baseline in the BARI 2D Cohort: Journal of the Peripheral Nervous System. 2009, 14:1-13.
20. Kellogg AP, Converso K, Wiggin T, Stevens MJ **and Pop-Busui R**: Effects of Cyclooxygenase-2 Gene Inactivation on Cardiac Autonomic and Left Ventricular Function in Experimental Diabetes. American Journal of Physiology- Heart and Circulatory Physiology. 2009, 296(2):H453-61.

21. Williams J, Pomeroy NE, **Pop-Busui R**, Lash R, Douyon L, Chames M, Wyckoff J: Case Report: Exenatide Use During Pregnancy. The Endocrinologist. 2009, 19:119-121.
 22. Pambianco G, Lombardero M, Bittner V, Forker A, Kennedy F, Krishnaswami A, Mooradian A, **Pop-Busui R**, Rana J, Rodriguez A, Steffes M, Orchard TJ: Control of Lipid at Baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Preventive Cardiology. 2009, 12 (1):9-18.
 23. **Pop-Busui R**, Low P, Waberski B, Martin CL, Albers J, Feldman EL, Sommer C, Cleary P, Lachin J, Herman WH for the DCCT/EDIC Research Group. Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Circulation. 2009, 119 (22):2886-93.
- Comment 1:** An editorial regarding this manuscript was published in Circulation. 2009, 9;119 (22):2886-93.
- Comment 2:** This paper was also highlighted under the Research Highlights section of Nature Reviews/Cardiology. 2009, Vol 6:496.
24. **Pop-Busui R**, Oral E, Pennathur S, Raffel D, Byun J, Bajirovic V, Vivekanandan A, Kellogg AP, Stevens MJ: Impact Of Rosiglitazone And Glyburide On Nitrosative Stress And Myocardial Blood Flow Regulation In Type 2 Diabetes: A 6 Month Randomized Trial. Metabolism. 2009, 58 (7):989-94.
 25. **Pop-Busui R**, Lombardero M, Lavis V, Foker A, Green J, Korytkowski M, Sobel B, Jones T and the BARI 2D Study Group. Highly Stenotic Coronary Artery Lesions are Less Frequent with Insulin Use or Thiazolidinedione Use in the BARI 2D Cohort at Baseline. American Journal of Cardiology. 2009, 104 (1):52-8.
 26. Wiggin TD, Sullivan KA, **Pop-Busui R**, Amato A, Sima AAF, Feldman EL: Elevated Triglycerides Precede Progression of Diabetic Neuropathy. Diabetes. 2009, 58 (7):1634-40.
 27. Eyvazzadeh AD, **Pop-Busui R**, Sowers MF, Zubieta J-K, Smith YR: The Role of the Endogenous Opioid System in Polycystic Ovary Syndrome. Fertility and Sterility. 2009, 92:1-12.
 28. Vincent AM, Hinder LM, **Pop-Busui R**, Feldman EL: Hyperlipidemia: A New Therapeutic Target for Diabetic Neuropathy. Journal of the Peripheral Nervous System. 2009, 14 (4):257-67.
 29. **Pop-Busui R**, Roberts L, Brosius FC, Pennathur S, Kretzler M, Feldman EL: The Management of Diabetic Neuropathy in Chronic Kidney Disease and Dialysis Patients. American Journal of Chronic Kidney Disease. 2010, 55 (2):365-85.

30. **Pop-Busui R:** Cardiac Autonomic Neuropathy in Diabetes- A clinical perspective. **Invited review** Diabetes Care. 2010, 33 (2):434-41.
31. Rana JS, Hardison RM, **Pop-Busui R**, Brooks, MM, Jones TLZ, Nesto RW, Bourassa MG and the BARI 2 D Investigators. Resting Heart Rate and Metabolic Syndrome in Patients with Diabetes and Coronary Artery Disease in Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Preventive Cardiology. 2010, Summer 13 (3):112-116.
32. Albers JW, Herman WH, Feldman EL, **Pop-Busui R**, Martin CL, Cleary P, Waberski BH, Lachin J for the DCCT/EDIC Research Group. Effect of Prior Intensive Insulin Therapy on Peripheral Neuropathy in Type 1 Diabetes. Diabetes Care. 2010, 33 (5):1090-6.
33. Calles-Escadron J, Lovato L, Simons-Morton D, Kendal D, **Pop-Busui R**, Cohen R, Fonseca V, Bonds D, Ismail-Beigi F, Benarji M, Failor A, Hamilton B: Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The ACCORD trial . Diabetes Care. 2010, 33 (4):721-7.
34. **Pop-Busui R**, Evans G, Fonseca V, Gerstein H, Prineas R, Genuth S, Fleg J, Grimm R, Corson M: Measures of Cardiac Autonomic Neuropathy and Relationship with Cardiovascular Mortality in the ACCORD Participants. Diabetes Care. 2010, 33 (7):1578-85.

Comment: Highlighted by the journal as the featured original research of the month (July 2010)

35. Ismail-Beigi F, Craven T, Basile J, Calles J, Cohen R, Cuddihy R, Cushman W, Genuth S, Grimm R, Hamilton B, Hoogwerf B, Karl D, Katz L, O'Connor P, **Pop-Busui R**, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I: Effects of intensive treatment of hyperglycemia on microvascular complications of type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. The Lancet. 2010, 376 (9739):419-30.
36. **Pop-Busui R**, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albers JW for the DCCT/EDIC Research Group. DCCT and EDIC studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History. Current Diabetes Reports. 2010, 10 (4):276-82.
37. Martin CL, Waberski BH, **Pop-Busui R**, Cleary P, Catton S, Albers JA, Feldman EL, Herman WH for the DCCT/EDIC Research Group. Vibration Perception Threshold as a Measure of Distal Symmetrical Peripheral Neuropathy in Type 1 Diabetes: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Diabetes Care. 2010, 33 (12):2635-41.
38. Callaghan BC, Liu J, Kerber K, **Pop-Busui R**, Feldman EL, Karter A: Triglycerides and Amputation Risk in Patients with Diabetics: 10 Year Follow-Up In The DISTANCE Study. Diabetes Care, 2011, 34 (3):635-40.

39. Piya MK, Shivu GN, Tahrani A, Dubb K, Abozguia, Phan TT, Narendran P, **Pop-Busui R**, Frenneaux M, Stevens MJ: Abnormal Left Ventricular Torsion and Cardiac Autonomic Dysfunction in Subjects with Type 1 Diabetes. Metabolism, 2011, 60 (8):1115-21.
40. Berent-Spillson A, Love T, **Pop-Busui R**, Sowers MF, Persad C, Pennington C, Eyvazaddeh A, Padmanabham V, Zubieta JK, Smith YR: Insulin Resistance Influences Central Opioid Activity in Polycystic Ovary Syndrome. Fertil Steril. 2011 Jun 30; 95 (8):2494-8.
41. Ellingrod VL, Taylor SF, Brook RD, Evans SJ, Zoellner SK, Grove TB, Bly MJ, **Pop-Busui R**, Dalack G: Dietary, Lifestyle and Pharmacogenetic Factors Associated with Arteriole Endothelial-Dependent Vasodilatation In Schizophrenia Patients Treated with Atypical Antipsychotics (AAPs). Schizophrenia Research. 2011 Aug; 130(1-3):20-6.
42. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, **Pop-Busui R**, Stevens M, Kempler P, Hilsted J, Tesfaye S, Low P, Valensi P; on behalf of the Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab. Res. Rev. 2011, 27 (7):639-653.
43. Bernardi L, Spallone V, Stevens M, Hilsted J, Frontoni S, **Pop-Busui R**, Ziegler D, Kempler P, Freeman R, Low P, Tesfaye S, Valensi P; on behalf of the Toronto Consensus Panel on Methods of Investigation for Cardiac Autonomic Dysfunction in Human Research Studies. Diabetes Metab. Res. Rev. 2011, 27 (7):654-664.
44. Kempler P, Amarenco G, Freeman R, Frontoni S, Horowitz M, Stevens M, Low PA, **Pop-Busui R**, Tahrani AA, Tesfaye S, Ziegler D, Valensi P on behalf of the Toronto Consensus Panel on Management strategies for gastrointestinal erectile, bladder and sudomotor dysfunction in patients with diabetes. Diabetes Metab. Res. Rev. 2011, 27 (7):665-677.
45. Gianchandani RY, Saberi, S, Zrull CA, Patil PV, Jha L, Kling-Colson, SC, Gandia, KG, DuBois, EC, Plunkett, CD, Bodnar TW, **and Pop-Busui R**: Evaluation of Hemoglobin A1c Criteria to Assess Preoperative Diabetes Risk in Cardiac Surgery Patients. Diabetes Technology and Therapeutics. 2011, (12):1249-54.
46. Vivekanandan-Giri A, Slocum, JL, Buller, CL, Basrur V, Ju W, **Pop-Busui R**, Lubman DM, Kretzler M Pennathur S: Urine Glycoprotein Profile Reveals Novel Markers for Chronic Kidney Disease. International Journal of Proteomics. 2011, (2011):1-18.
47. Rawlings RA, Shi H, Yuan L, Brehm W, **Pop-Busui R**, Nelson P. Translating Glucose Variability Metrics into the Clinic via Continuous Glucose Monitoring: a Graphical User Interface for Diabetes Evaluation (CGM-GUIDE ©)". Diabetes Technology and Therapeutics. 2011, (12):1241-8.

48. Chandra P, Sands RL, Giles pie BW, Levin NW, Kotanko P, Kieser M, Finkelstein F, Hinderliter A, **Pop-Busui R**, Saran R. Predictors of heart rate variability and its prognostic significance in chronic kidney disease. Nephrol. Dial. Transplant. 2012 Feb; 27 (2):700-9.
49. Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zöllner SK **and Pop-Busui R**. Risk Factors Associated with Metabolic Syndrome in Bipolar and Schizophrenia Subjects Treated With Antipsychotics: The Role of Folate Pharmacogenetics. Journal of Clinical Psychopharmacology. 2012 Apr; 32 (2):261-5.
50. Herman WH, **Pop-Busui R**, Braffett BH, Martin CL, Cleary PA, Albers JW, Feldman EL and The DCCT/EDIC Research Group. Use of the Michigan Neuropathy Screening Instrument (MNSI) as a Measure of Distal Symmetrical Peripheral Neuropathy (DSPN) in Type 1 Diabetes: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Diabetic Medicine. 2012, 29 (7):937-44.
51. Gianchandani RY, Esfandiari N, Haft JW, Prager RL **and Pop-Busui R**. Diabetes Mellitus and Stress Hyperglycemia in the Intensive Care Unit; Outcomes after Cardiac Surgery. Hospital Practice 2012, 40 (2):22-30.
52. Rawlings RA, Shi H, Yuan L, Brehm W, **Pop-Busui R**, Nelson P. Dynamic Stress Factor (DySF): a Significant Predictor of Severe Hypoglycemic Events in Children with Type 1 Diabetes. Journal of Diabetes and Metabolism, 2012;3: 177
53. Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, **Pop-Busui R**, Taillefer R, Chaitman BR, Gibbons RJ, Heo J, Iskandrian AE. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Journal of Nuclear Cardiology, 2012, 19 (4):658-69.
54. **Pop-Busui R**. What Do We Know and We do not Know about Cardiovascular Autonomic Neuropathy in Diabetes. **Invited review.** Journal of Cardiovascular Translational Research, 2012, 5 (4):463-478.
55. Petrou M, **Pop-Busui R**, Foerster BR, Edden RA, Callaghan BC, Harte SE, Harris RE, Clauw DJ, Feldman EL. Altered excitation-inhibition balance in the brain of patients with diabetic neuropathy. Academic Radiology, 2012, 19 (5):607-12.
56. Burghardt KJ, **Pop-Busui R**, Bly MJ, Grove TB, Taylor SF, Ellingrod VL. The influence of the brain-derived neurotrophic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations. Clin. Transl. Sci. 2012 (6): 486-90
57. **Pop-Busui R**, Cleary PA, Braffett BH, Martin CL, Herman WH, Low PA, Lima JAC, Bluemke DA and the DCCT/EDIC Research Group. Association between Cardiovascular

Autonomic Neuropathy and Left Ventricular Dysfunction in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Journal of the American College of Cardiology, 2013, 61 (4):447-54.

58. Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, **Pop-Busui R**, Riddle MC; the ACCORD Study Group Determinants of Weight gain in the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care, 2013, 36 (8): 2162-8.
59. Marsh CA, Berent-Spillson A, Love T, Persad CC, **Pop-Busui R**, Zubieta JK, Smith YR. Functional neuroimaging of emotional processing in women with polycystic ovary syndrome: a case-control pilot study. Fertil Steril. 2013 100 (1):200-207.
60. **Pop-Busui R**, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TLZ. Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care 2013;36(10):3208-15
61. **Pop-Busui R**, Stevens MJ, Raffel DM, White EA, Mehta M, Plunkett CD, Brown MB, Feldman EL. Effects of Triple Antioxidant Therapy on Measures of Cardiovascular Autonomic Neuropathy and on Myocardial Blood Flow in Type 1 Diabetes. Diabetologia, 2013, 56:1835-1844.
62. Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, Perkins BA, **Pop-Busui R**, Rossing P, Mauer M, Doria A; PERL Consortium. Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study. Curr Diab Rep. 2013 Aug; 13(4):550-9.
63. Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber AJ, Kennedy L, Monrad ES, **Pop-Busui R**, Kelsey SF, Frye RL; for the BARI 2D Investigators. Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2013, Aug 20;128(8):785-794.
64. Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, Pettitt DJ, Saydah S, Pihoker C, Standiford DA, Rodriguez BL, **Pop-Busui R**, Feldman EL, for the SEARCH for Diabetes in Youth Study “Peripheral Neuropathy in Adolescents and Young Adults with Type 1 and Type 2 diabetes from the SEARCH for Diabetes in Youth Follow-Up Cohort: A Pilot Study”, Diabetes Care 2013, Dec. 36: 3903-3908.
65. Hur J, Sullivan KA, Callaghan BC, **Pop-Busui R**, Feldman EL. Identification of Factors Associated With Sural Nerve Regeneration and Degeneration in Diabetic Neuropathy. Diabetes Care. 2013 Dec. 36:4043-4049.

66. Bly MJ, Taylor SF, Dalack G, **Pop-Busui R**, Burghardt KJ, Evans, SJ, McInnis MI, Grove TB, Brook RD, Zollner SK, Ellingrod VL, Metabolic Syndrome in Bipolar Disorder and Schizophrenia: Dietary and Lifestyle Factors Compared to the General Population. Bipolar Disorders 2014, May; 16: 277-288.
67. Jaiswal M, Schinke A, and **Pop-Busui R**. Invited Review. Lipids and Lipid Management in Diabetes. Best Practice & Research Clinical Endocrinology & Metabolism 2013, 2014 Jun.28 (3):325-38. PMID:24840262.
68. Martin CL, Albers JW and **Pop-Busui R**. Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Invited Review for the 30th Anniversary of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Special Issue Diabetes Care, 2014 January, 37:31-8.
69. Albers JW and **Pop-Busui R**. Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes. Curr Neurol Neurosci Rep. 2014 14:473, pgs. 1-11.
70. Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, **Pop-Busui R**, Kelsey SF, Frye RL and BARI 2D Investigators. Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2014 Apr 22;129(16):e460-1. doi: 10.1161
71. Srinivasan A, Kim B, Feldman EL and **Pop-Busui R**. Diffusion Tensor Imaging of the Sural Nerve in normal controls. Clinical Imaging. 2014, 38(5):648-54
72. Ang L, Jaiswal M, Martin CL, and **Pop-Busui R**. Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials. Current Diabetes Reports. 2014, Sep; 14 (9):528
73. Stem MS, Hussain M, Lentz S, Raval N, Gardner T, **Pop-Busui R**, Shtein RM. Differential reduction in corneal nerve fiber length in patients with type 1 or type 2 diabetes mellitus. Journal of Diabetes and Its Complications. 2014, Sep-Oct. 28 (5):658-61.
74. Jaiswal M, McKeon K, Comment N, Henderson J, Swanson S, Nelson P, and **Pop-Busui R**. Association between Impaired Cardiovascular Autonomic Function and Hypoglycemia in Patients with Type 1 Diabetes. Diabetes Care, 2014, 37: 2616-21
75. The Working Group of Neurodiab, Biessels GJ, Bril V, Calcutt NA, Cameron NE, Cotter MA, Dobrowsky R, Feldman EL, Fernyhough P, Jakobsen J, Malik RA, Mizisin AP, Oates PJ, Obrosova IG, **Pop-Busui R**, Russell JW, Sima AA, Stevens MJ, Schmidt RE, Tesfaye S, Veves A, Vinik AI, Wright DE, Yagihashi S, Yorek MA, Ziegler D, Zochodne DW. Phenotyping Animal Models of Diabetic Neuropathy: A Consensus Statement of the Diabetic Neuropathy Study Group of the EASD (Neurodiab). Journal of the Peripheral Nervous System. 2014, 19(2):77-87. PMID:24934510.

76. Wrobel J, Ammanath P, Le T, Wensman J, Grewal G, Najafi B, Pop-Busui R. A Novel Shear Reduction Insole Effect on the Thermal Response to Walking Stress, Balance, and Gait. Journal of Diabetes Science and Technology. 2014, J Diabetes Sci Technol. 2014 8(6):1151-6 PMID: 25107709.
77. Wei N, Pan J, **Pop-Busui R**, Othman A, Alecu I, Hornemann T, Eichler FS. Altered Sphingoid Base Profiles in Type 1 Compared to Type 2 Diabetes. Lipids Health Dis. 2014 Oct 11;13(1):161. PMID:25305670.
78. **Pop-Busui R**, Hotaling J, Braffett B, Cleary PA, Dunn RL, Martin CL, Jacobson AL, Wessells H, Aruna V. Sarma for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Cardiovascular Autonomic Neuropathy, Erectile Dysfunction and Lower Urinary Tract Symptoms in Men with Type 1 Diabetes: Findings from the DCCT/EDIC. J of Urology, 2015, 193 (6): 20145-51. PMID: 25584994
79. Lovlom E, Cherney D, **Pop-Busui R**, Perkins BA. Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Non-Macroalbuminuric Type 1 Diabetes. Clinical Journal of the American Society of Nephrology. 2015. 10 (7): 1136-44, PMID: 26092828.
80. Jaiswal M, Martin CL, Brown MB, Callaghan B, Albers JW, Feldman EL **and Pop-Busui R**. Effects of Exenatide on Measures of Diabetic Neuropathy in Subjects with Type 2 Diabetes: Results from an 18-month Proof-of-Concept Open Label Randomized Study. Journal of Diabetes and Its Complications. 2015. Jul 17. pii: S1056-8727(15)00285-8. doi: 10.1016/j.jdiacomp.2015.07.013. [Epub ahead of print] PMID: 26264399.
81. Gianchandani R, Saberi S, Patil P, Prager R, **and Pop-Busui R**. Prevalence and determinants of glycemic abnormalities in cardiac surgery patients without a history of diabetes: a prospective study. Frontiers in Endocrinology. 2015, 6: 125, PMID:26322019
82. Kim C, **Pop-Busui R**, Braffett B, Cleary PA, Bebu I, Wessells H, Orchard T, Sarma A. Testosterone Concentrations and Cardiovascular Autonomic Neuropathy in Men with Type 1 Diabetes in the Epidemiology of Diabetes Interventions and Complications Study (EDIC). Journal of Sexual Medicine. In press.
83. DeMill D, Hussain M, **Pop-Busui R**, Shtein RM. Ocular Surface Disease in Patients with Diabetic Peripheral Neuropathy. British Journal of Ophthalmology. Br J Ophthalmol. 2015 Oct 23. pii: bjophthalmol-2015-307369. doi: 10.1136/bjophthalmol-2015-307369.
84. Kim SG, **Pop-Busui R**. Body mass index and mortality in the general population and in subjects with chronic disease in Korea: A Nationwide Cohort Study (2002-2010). PLOS ONE. 2015 Oct 13;10(10):e0139924. doi: 10.1371
85. **Pop-Busui R**, Ang L, Holmes C, Gallagher C, Feldman EL. Inflammation as Therapeutic Target in Diabetic Neuropathy. Current Diabetes Reports. In press.

BOOKS AUTHORED/CHAPTERS IN BOOKS

1. **Pop-Busui R**: The Porphyrins. In: Little Textbook of Metabolic Diseases edited by Serban V. Excelsior Edit, Timisoara, Romania, 143-157, 1994.
2. Stevens MJ, **Pop-Busui R**, Greene DA, Feldman EL: Pathogenesis of Diabetic neuropathy. In: Porte D Jr, Sherwin R, Rifkin H (Eds): Ellenberg and Rifkin's Diabetes Mellitus, 6th edition (Stamford, CT: Appleton & Lange, 2002).
3. **Pop-Busui R**, Stevens MJ: Animal models of diabetic neuropathy. In: Cheta D (Ed) New Insights in Experimental Diabetes, Romanian Academy Printing House, 277-330, 2002.
4. **Pop-Busui R**, Stevens MJ: Insulin and Cardiovascular Disease in Type 2 Diabetes. In: Cheta D (Ed) Vascular Involvement in Diabetes: Clinical and Experimental Data, Romanian Academy Printing House & S. Karger AG; Bucharest & Basel, 653- 658, 2005.
5. **Pop-Busui R**: New Drugs for Diabetes. In: Hancu N, De Leiva A (Eds). Pharmacotherapy of Diabetes Mellitus: Evidence and Controversies, Springer Verlag, Berlin, New York, 2006.
6. **Pop-Busui R**, London, Z, Kellogg, AP: Diabetes and Endocrine Disorders. In: Gilman S (Ed). Neurobiology of Disease, Elsevier Academic Press, Elsevier Inc., 669-680, 2007.
7. **Pop-Busui R**, Sullivan K, Feldman EL: Diabetes and the Nervous System. In: Neurology and General Medicine, 4th Edition, Chapter 21, Aminoff MJ (Ed). Elsevier, Philadelphia, PA, 383-408, 2008.
8. **Pop-Busui R**, Stevens MJ: Detection and Treatment of Chronic Complications. In: Medical Management of Type 2 Diabetes, 6th Edition, Burant CF (Ed) American Diabetes Association Inc, 105-138, 2008.
9. **Pop-Busui R**, Feldman EL: Diabetic Neuropathies - a Clinical Monograph. In: British Medical Journals, published online 2009, with an updates published 2010, 2012, and 2015, available at US version: <http://online.epocrates.com> and International version: <http://bestpractice.bmj.com/best-practice/welcome.html>
10. **Pop-Busui R**, Simmons Z, Feldman EL: Treatment of Diabetic Neuropathy. In: Herman WH, Kinmonth AL, Wareham NJ, Williams R (Eds) The Evidence Base for Diabetes Care. First Edition, Chapter 19. Wiley-Blackwell Publications, John Willey& Sons Ltd, 317-340, 2010.
11. **Pop-Busui R**, Dragomir A, Guja C, Cheta D. Genetic Features of the Main Co-morbidities in Diabetes. In: D Cheta (Ed) Genetics of Diabetes-The Truth Unveiled, Romanian Academy Printing House & S. Karger AG; Bucharest & Basel, 335-367, 2010.

12. **Pop-Busui R**, Holmes C, Stevens MJ: Can I Prevent Problems in the at Risk Diabetic Foot? In: AH Barnett (Ed) Clinical Challenges in Diabetes, Atlas Medical Publishing Ltd, Oxford UK, 125-140, 2010.
13. **Pop-Busui R**, Pietropaolo M: Metabolic syndrome and inflammation. In: Eisenbarth's (Ed): Immunoendocrinology: Scientific and Clinical Aspects, Humana Press, Springer New York, Dordrecht, Heidelberg, London; 69-94, 2011.
14. **Pop-Busui R**, Stevens MJ: Detection and Treatment of Chronic Diabetes Complications. In: Medical Management of Type 2 Diabetes, 7th Edition, Burant CF (Ed) American Diabetes Association Inc, 2012.
15. **Pop-Busui R**. Diabetic Neuropathies. In Clinical Decision Support Digital Program on Endocrinology, 2013, Rosen, Adler, Braverman, Clemmons, Klibanski, and Thomas (Eds). <http://www.decisionsupportinmedicine.com/authorworkflow>.
16. **Pop-Busui R**, Schmid H. Cardiovascular Autonomic Neuropathy. In Diabetic Neuropathies (Neuropatias e Pe Diabetico), 2014, Hermelinda C Pedrosa, Lucio Vilar, Andrew JM Boulton (Eds), Grupo Editorial Nacional, AC Farmaceutica, Sao Paolo, 42-72.
17. **Pop-Busui R**, M Mehta, S Pennathur. Oxidative Stress and Cardiovascular Disease in Diabetes. In: "Studies in Diabetes" Oxidative Stress in Applied Basic Research and Clinical Practice; Obrosova et al (Eds) , Springer Science, New York, 2014.
18. **Pop-Busui R**, Albers A, Feldman EL. Peripheral Neuropathies in Diabetes. Chapter 44. In *Therapy for Diabetes Mellitus and Related Disorders, 6th edition*. Umpierrez GE, Ed. Alexandria, VA, American Diabetes Association, 2014. P.793-833.
19. **Pop-Busui R**, Stevens M. Autonomic Neuropathy in Diabetes. Chapter 45. In *Therapy for Diabetes Mellitus and Related Disorders, 6th edition*. Umpierrez GE, Ed. Alexandria, VA, American Diabetes Association, 2014, p.834-863.
20. **Pop-Busui R**, Boulton AJM, Sosenko JM. Peripheral and Autonomic Neuropathy in Diabetes. In *Diabetes in America, 3rd Edition*. The National Diabetes Data Group of the National Institute of Diabetes and Digestive and Kidney Diseases, Ed. National Institutes of Health, Bethesda, MD. Chapter 23, In press.

OTHER MEDIA

1. **Pop-Busui R**, contributing author and member of American Diabetes Association Clinical Practice Committee in charge. Clinical Practice Recommendations, Diabetes Care. Suppl 1 January 2014. S1-S88.
2. **Pop-Busui R**, contributing author and member of the American Diabetes Association Clinical Practice Committee in charge. Standards of Medical Care in Diabetes 2015. Diabetes Care. Suppl 1 January 2015. S1-S90.

ABSTRACTS

1. Bacanu GH, **Pop-Busui R**, Sporea I, Vernic C.: Is gallstone disease more frequent in diabetic patients? *Acta Diabetica Romania*, 1992, 18 Suppl, 4, Romanian Diabetes Association Annual Meeting 1992, Bucharest Romania.
2. Negrisanu G, **Pop-Busui R**, Munteanu M: Effects of treatment with capsaicin on painful peripheric diabetic neuropathy. *Acta Diabetica Romana*, 1993, 19 Suppl, 36; Romanian Diabetes Association Annual Meeting 1993 Brasov Romania.
3. Serban V, **Pop-Busui R**, Avram R: Relationship of diabetes mellitus and inflammatory joint diseases. *Acta Diabetica Romana*, 1993, 19 Suppl 47; Romanian Diabetes Association Annual Meeting 1993.
4. **Pop-Busui R**, Bacanu GH, Serban V, Negrisanu G, Vernic C: Relationship between gallstones disease and obesity in diabetic patients. *International Journal of Obesity*. 1993; 17 Suppl 2 59. European Association for the Study of Obesity Annual Meeting, Ulm Germany, 1993.
5. Sporea I, **Pop-Busui R**, Molnar C, Goldis A: The study of gallbladder ejection fraction in patients with diabetes mellitus. *Revue of the International Congress of Internal Medicine*. International Internal Medicine Society Annual Meeting Budapest 1994.
6. Bacanu GH, **Pop-Busui R**, Serban V, Clepe D: Aspects of the diabetic foot. Abstracts volume of the 3rd European Meeting for the Implementation of the St Vincent Declaration, 1994.
7. **Pop-Busui R**, Sporea I, Bacanu GH, Serban V: Effect of cisapride and erythromicine on gastric emptying in diabetic patients. *Diabetologia*. 1995; 38 Suppl 1 A245. European Association for the Study of Diabetes (EASD) Annual Meeting, Stockholm 1995.
8. **Pop-Busui R**, Van Huysen C, Beyer L, Towns R, Greene DA, Stevens MJ: Correction of nerve conduction velocity slowing but not nerve blood flow deficit by acetyl-L carnitine in streptozotocin diabetes. *Diabetologia*. 1996; 39 Suppl 1 A249.
9. **Pop-Busui R**, Van Huysen C, Beyer L, Towns R, Greene DA, Stevens MJ: Dissociation of nerve blood flow and motor nerve conduction velocity by acetyl-L carnitine in streptozotocin diabetes. *Diabetes*. 1996;45 Suppl 2 5A-12.
10. **Pop-Busui R**, Forman L, Van Huysen C, Greene DA, Stevens MJ: Correction of nerve ATPase activity and blood flow deficits by enalapril in the streptozotocin-diabetic rat. *Diabetes*. 1997; 46, Suppl 1 0278-71 A.
11. **Pop-Busui R**, Van Huysen C, Beyer L, Stevens MJ: Nerve taurine replacement attenuates oxidative stress, nerve blood flow and conduction deficits in streptozotocin-diabetic rats. *Diabetologia*. 1997;40 Suppl 1 2174-A553.

12. **Pop-Busui R**, Obrosova I, Van Huysen C, Beyer L, Stevens MJ. Attenuation of oxidative stress and nerve vascular and functional deficits by nerve taurine replacement in the streptozotocin-diabetic rat. *Journal of the Peripheral Nervous System*. 1997;2:293.
13. **Pop-Busui R**, Forman L, Van Huysen C, Greene DA, Stevens MJ: Amelioration of nerve ATPase activity and blood flow deficits by enalapril in the streptozotocin-diabetic rat. *Journal of the Peripheral Nervous System*. 1997;2:292.
14. **Pop-Busui R**, Van Huysen, Bayer L, Cao X, Obrosova I, Stevens MJ: The attenuation of nerve vascular and functional deficits by nerve taurine replacement in the streptozotocin-diabetic rat. *Diabetes*. 1998;47 Suppl 1 0537-A137.
15. **Pop-Busui R**, Towns R, Larkin D, Stevens MJ: Down-regulation of sciatic nerve Na⁺-taurine co-transporter in streptozotocin-diabetic rats- a potential mediator of glucose-toxicity. *Diabetologia*. 1998;41 Suppl 1 A50-190.
16. **Pop-Busui R**, Towns R, Larkin D, Killen PD, Greene DA: Anti-peptide antibodies detect distinct sodium-dependent *myo*-inositol (MI) cotransporter (SMIT) isoforms in human retinal pigment epithelial (RPE) cells. *Journal of the American Society of Nephrology*, 1998;9, 56 A-A 0291.
17. **Pop-Busui R**, Marinescu V, Towns R, Larkin D, Sullivan K, Stevens MJ: Down-regulation of sciatic nerve Na⁺-taurine co-transporter in streptozotocin-diabetic rats: a potential mediator of nerve ischemia. *Diabetes*. 1999;48 Suppl 1 A638-A148.
18. **Pop-Busui R**, Kirkwood I, Wieland D, Raffel D, Stevens MJ: Myocardial endothelial Dysfunction complicates sympathetic dysinnervation in diabetic autonomic neuropathy. *Diabetes*. 1999;48 Suppl 1 A 233-A55.
19. Nakashima E, **Pop-Busui R**, Larkin D, Towns R, Masterson J, Killen PD, Stevens MJ, Greene DA: Dissociation of Na-Myo-Inositol (MI) Cotransporter (SMIT) peptide abundance from gene expression and activity by glucose in human retinal pigment epithelial (RPE) cells. *Diabetes*. 2000;49 Suppl 1 A169-43.
20. **Pop-Busui R**, Marinescu V, Sedey KA, Stockert C, Carey S, Greene DA, Stevens MJ: Metabolic, vascular and nerve conduction deficits induced by cyclooxygenase inhibition in experimental diabetes. *Diabetes*. 2000;49 Suppl 1 A34-140.
21. **Pop-Busui R**, Sullivan K, Towns R, Larkin D, Stevens MJ: Tissue localization and regulation of expression of Na-taurine cotransporter in streptozotocin-diabetes rats. The Endocrine Society's 82nd Annual Meeting 2000 Abstract Book, 335:89.
22. **Pop-Busui R**, Sullivan K, Marinescu V, Greene DA, Stevens MJ: Taurine replacement prevents apoptosis in experimental diabetic neuropathy. Fifth Diabetic Neuropathy Satellite to the International Diabetes Federation Congress 2000, San Jose, Costa Rica, Abstract Book.

23. **Pop-Busui R**, Weiss C, Stevens MJ: New Onset Graves' Disease, Type 1 diabetes and Cerebellar Ataxia associated with Glutamic Acid Decarboxylase (GAD) Autoantibodies. The Endocrine Society's 83rd Annual Meeting 2001 Abstract Book, P2-689, 441.
24. **Pop-Busui R**, Marinescu V, Larkin D, Lum M, Stevens MJ: Cyclooxygenase (COX)-2 expression is selectively increased in the sciatic nerve of streptozotocin diabetic (STZ-D) rats. The Endocrine Society's 83rd Annual Meeting 2001 Abstract Book, P1-361, 225.
25. **Pop-Busui R**, Marinescu V, Larkin D, Lum M, Stevens MJ: Cyclooxygenase (COX)-2 expression is selectively increased in the sciatic nerve of streptozotocin diabetic (STZ-D) rats. Diabetes 49, 2001, Suppl 1.
26. **Pop-Busui R**, Raffel D, Marinescu V, Stevens MJ: Oxidative Stress is Associated with Abnormal Myocardial Blood Flow Regulation in Subjects with Type 1 Diabetes and Microangiopathy. Diabetes 49, 2001, Suppl 1.
27. **Pop-Busui R**, Raffel D, Stevens MJ: C - reactive protein is associated with abnormal myocardial blood flow regulation in subjects with Type 1 Diabetes and Microangiopathy. Diabetes 51, 2002 Suppl 2, A198.
28. Stevens MJ, **Pop-Busui R**, Schroeder J, Raffel D: Impaired Myocardial Blood Flow regulation complicates asymptomatic type 2 diabetes. Diabetes, 52, 2003, Suppl 1, A197.
29. **Pop-Busui R**, Kellogg AP, Li F, Larkin D, Stevens MJ: Cox-2-Knock-Out Mice are Protected from Nerve Conduction Velocity Slowing In Experimental Diabetes. Diabetes, 52, 2003, Suppl 1, A196.
30. **Pop-Busui R**, Kellogg AP, Li F, Larkin D, Stevens MJ: Cox-2-Knock-Out Mice are Protected from Nerve Conduction Velocity Slowing in Experimental Diabetes. Journal of the Peripheral Nervous System, 8, 2003, 178.
31. Stevens MJ, Schroeder J, Raffel D, **Pop-Busui R**: Adrenergic Hyper-Responsiveness and Paradoxical Myocardial Blood Flow Regulation Complicate Type1 but Not Type 2 Diabetes Mellitus. Journal of the Peripheral Nervous System, 8, 2003, 182.
32. **Pop-Busui R**, Kellogg AP, Li F, Larkin D, Stevens MJ: Effects of COX-2 Gene Inactivation on Nerve Conduction Velocity and Oxidative Stress in Experimental Diabetes. Diabetes, 53, 2004, Suppl.
33. **Pop-Busui R**, Kellogg AP, Li F, Larkin D, Stevens MJ: Effects of COX-2 Gene Inactivation on Nerve Conduction Velocity and Oxidative Stress in Experimental Diabetes. III. DFSG and NEURODIAB Joint Meeting Abstract Book 189.
34. **Pop-Busui R**, Kellogg AP, Li F, Larkin D, Stevens MJ: Effects of Cyclooxygenase (COX) Inhibition on Nerve Conduction Velocity (NCV) and Sensory Fiber Function in Experimental Diabetes. NEURODIAB XV Abstract Book 28, 2005.

35. Kellogg AP, Larkin D, Stevens MJ, **Pop-Busui R**: Protective Effects of Cyclooxygenase-2 (COX-2) Gene Inactivation on Functional and Biochemical Deficits of Experimental Diabetic Neuropathy are maintained after Longer Diabetes Duration. NEURODIAB XV Abstract Book 29, 2005.
36. Kellogg AP, Shidyak A, Larkin D, Stevens MJ, **Pop-Busui R**: Effects of Cyclooxygenase-2 (COX-2) Gene Inactivation on Myocardial Oxidative Stress and Inflammation in Experimental Diabetes. *Circulation*, 112, 17, Suppl 2, 174.
37. Kellogg AP, Larkin D, **Pop-Busui R**: Long Term Protective Effects of Cyclooxygenase-2 (COX-2) Gene Inactivation on Functional Deficits of Experimental Diabetic Neuropathy. *Diabetes*, 55, 2006, Suppl 1, A189.
38. **Pop-Busui R**, Stevens MJ, Raffel D, Plunkett C, Russell J, Brosius F and Feldman EL: Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial. NEURODIAB XVI Abstract Book 64, 2006.
39. Kellogg AP, Larkin D, Feldman EL Stevens MJ, **Pop-Busui R**: Cross Talk between Cyclooxygenase-2 (COX-2) pathway, oxidative stress and inflammation in long term experimental diabetic neuropathy. NEURODIAB XVI Abstract Book 85, 2006.
40. **Pop-Busui R**, Lu J, Lopes N, Jones TL: Prevalence of Diabetic Peripheral Neuropathy (DPN) and Relation to Glycemic Control Strategies at Baseline in the BARI 2D Cohort. *Diabetes*, 56, 2007, Suppl A.
41. **Pop-Busui R**, Pennathur S, Oral E, Raffel D, Byun J, Bajirovic V, Vivekanandan A, Kellogg AP, Stevens MJ: Rosiglitazone Ameliorates Nitrosative Stress and Inflammation in Type 2 Diabetes. *Diabetes*, 56, 2007, Suppl 2.
42. **Pop-Busui R**, Pennathur S, Oral E, Raffel D, Byun J, Bajirovic V, Vivekanandan A, Kellogg AP, Steven MJ: Rosiglitazone Ameliorates Nitrosative Stress and Preserves Myocardial Blood Flow in Type 2 Diabetes. NEURODIAB XVII Abstract Book 45, 2007.
43. **Pop-Busui R**, Low PA, Waberski BH, Martin CL, Feldman EL, Albers JW, Cleary P, Sommer C, Herman WH, and the DCCT/EDIC Research Group. Cardiac Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). *Diabetes*, 57, 2008, Suppl 1, A68.
44. Albers JW, Herman WH, Feldman EL, **Pop-Busui R**, Martin CL, Waberski BH, Cleary P, Lachin JM and the DCCT/EDIC Research Group. Neuropathy among Patients with Type 1 Diabetes 14 Years after a Trial of Intensive Therapy. *Diabetes*, 57, 2008, Suppl 1, A68.
45. Saberi S, **Pop-Busui R**, Fisher M, Gianchandani R: Stress-Induced Hyperglycemia: Predictors and Follow-Up. *Diabetes*, 57, 2008, Suppl 1, A156.

46. **Pop-Busui R**, Low PA, Waberski BH, Martin CL, Feldman EL, Albers JW, Cleary P, Sommer C, Herman WH, and the DCCT/EDIC Research Group. Cardiac Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). *Diabetologia*, 51, 2008, Suppl 1, S 106.
47. Martin CL, Waberski BH, **Pop-Busui R**, Albers JW, Herman WH, Cleary P: Same Day intra-subject reproducibility of vibration perception threshold in type 1 diabetes. *Diabetologia*, 51, 2008, Suppl 1, S 506.
48. **Pop-Busui R**, Low PA, Waberski BH, Martin CL, Feldman EL, Albers JW, Cleary P, Sommer C, Herman WH, and the DCCT/EDIC Research Group. Cardiac Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). *NEURODIAB XVIII Abstract Book* 34, 2008.
49. Albers JW, Herman WH, Feldman EL, **Pop-Busui R**, Martin CL, Waberski BH, Cleary P, Lachin JM and the DCCT/EDIC Research Group. Neuropathy among Patients with Type 1 Diabetes 14 Years after a Trial of Intensive Therapy. *NEURODIAB XVIII Abstract Book* 44, 2008.
50. **Pop-Busui R**, Raffel D, Byun J, Rubenfire M, Giri A, Ryan K, Brown M, Pennathur S: Oxidative Stress and Cardiovascular Denervation in Subjects with Metabolic Syndrome. *Journal of Diabetes*, Vol.1, Suppl 1, A76.
51. **Pop-Busui R**, Raffel D, Byun J, Rubenfire M, Giri A, Ryan K, Brown M, Pennathur S: Cardiovascular Denervation and Oxidative Stress in Subjects with Metabolic Syndrome. *Diabetes*, 58, 2009, Suppl 1, A62.
52. **Pop-Busui R**, Evans G, Gerstein H, Fonseca V, Hoogwerf B, Genuth S, Fleg J, Grimm R, Corson M, Prineas R, and the ACCORD Study Group: Cardiac Autonomic Dysfunction Predicts Cardiovascular Mortality in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *Diabetes*, 58, 2009, Suppl 1, A63.
53. **Pop-Busui R**, Cleary PA, Waberski B, Lachin J, Martin, C, Herman W, Low PA: Association between Hypoglycemia and Impaired Cardiovascular Autonomic Function in the DCCT/EDIC cohort. 8th International Symposium on Diabetic Neuropathy and 19th Annual Meeting of the Diabetic Neuropathy Study Group of the EASD-NEURODIAB Abstract Book, A 33: 41.
54. **Pop-Busui R**, Raffel D, Byun J, Giri A, Rubenfire M, Brown M, Ryan K, Pennathur S: Cardiovascular Denervation and Oxidative Stress in Subjects with Metabolic Syndrome. 8th International Symposium on Diabetic Neuropathy and 19th Annual Meeting of the Diabetic Neuropathy Study Group of the EASD- NEURODIAB Abstract Book, A 27: 38.

55. **Pop-Busui R**, Waberski BH, Cleary PA, Herman WH, Low PA, Martin CL, Lima JA, Bluemke D: Cardiac Autonomic Neuropathy and Left Ventricular Function in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). *Circulation*. 2009;120:S546-S547.
56. Herman WH, **Pop-Busui R**, Waberski BH, Martin CL, Cleary PA, Albers JW and Feldman EL: Validation of the Michigan Neuropathy Screening Instrument as a Measure of Distal Symmetrical Peripheral Neuropathy in Type 1 Diabetes: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). *Diabetes* 59, 2010, Suppl 1, A328.
57. Kim B, Chenevert T, Srinivasan A, Sabb B and **Pop-Busui R**: Diffusion Tensor Imaging of the Sural Nerves. Proceedings of International Society of Magnetic Resonance in Medicine, 3250, 18th Annual Meeting, Stockholm, Sweden, May, 2010.
58. Swanson SD, Mueller G, Raffel D, Happ D, Duvernoy CS and **Pop-Busui R**: Association between Left Ventricle Sympathetic Innervation and Torsion in Patients with Type 1 Diabetes. Proceedings of International Society of Magnetic Resonance in Medicine, 18th Annual Meeting, Stockholm, Sweden, May, 2010.
59. **Pop-Busui R**, Ewans GE, Gerstein H, Craven T, Fonseca V, Feldman EL, Fleg J, Prineas R, Genuth S, Lipkin E, Ismail-Beigi F: Effects of Intensive Risk Factor Management on Measures of Neuropathy in Participants with Type 2 Diabetes enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial, Abstract Book: O 22: 43, the 20th Annual NEURODIAB Meeting, Stockholm, Sweden, 2010.
60. **Pop-Busui R**, Herman WH, Martin CL, Waberski BH, Cleary PA, Albers JW and Feldman EL: Validation of the Michigan Neuropathy Screening Instrument as a Measure of Distal Symmetrical Peripheral Neuropathy in Type 1 Diabetes: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Abstract Book: P 45: 105, the 20th Annual NEURODIAB Meeting, Stockholm, Sweden, 2010.
61. **Pop-Busui R**, Low PA, Braffett BH, Martin CL, Feldman EL, Albers JW, Sommer C, Cleary PA and Herman WH: Progression of Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). *Diabetes* 60, 2011, Suppl 1, A 29-109 OR.
62. **Pop-Busui R**, Raffel D, Rubenfire M, Byun J, Giri A, Brown M, Ryan K and Pennathur S: Cardiovascular Autonomic Neuropathy, Oxidative Stress and Lifestyle Intervention in Subjects with Metabolic Syndrome. *Diabetes* 60, 2011, Suppl 1, A 173-630 P.
63. Martin CL, Braffett BH, **Pop-Busui R**, Feldman EL, Albers JW, Sommer C, Low PA, Cleary PA and Herman WH: Intra-Subject Reproducibility of Cardiac Autonomic Neuropathy Tests in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). *Diabetes* 60, 2011, Suppl 1, A 178-645P.

64. **Pop-Busui R**, Low PA, Braffett BH, Martin CL, Feldman EL, Albers JW, Sommer C, Cleary PA and Herman WH: Progression of Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Abstract Book: O16:40, the 21st Annual NEURODIAB Meeting, Porto, Portugal, 2011.
65. Martin CL, Braffett BH, **Pop-Busui R**, Feldman EL, Albers JW, Sommer C, Low PA, Cleary PA and Herman WH: Intra-Subject Reproducibility of Cardiac Autonomic Neuropathy Tests in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Abstract Book: P14:88, the 21st Annual NEURODIAB Meeting, Porto, Portugal, 2011.
66. Swanson SD, Mueller G, Raffel D, Duvernoy CS, Plunkett C, Stevens M and **Pop-Busui R**. Left Ventricle Function and Sympathetic Innervation in Type 1 Diabetes. Circulation, 2011, 124: A:15606.
67. Momont AC, Reed DM, Baciu P, Hussain M, Shtein RM, Mahmoud AM, Roberts CJ, **Pop-Busui R**, Moroi SE: Effect of Diabetes Mellitus on Central Corneal Thickness and Correlation with Optic Nerve Parameters. American Glaucoma Society, March, 2012.
68. Feldman EL, Martin CL, Bell RA, Lauer A, Divers J, Dabelea D, Pettitt DJ, Saydah S, Linder B, Pihoker C, Standiford DS, Rodriguez BL, **Pop-Busui R**, For the SEARCH for Diabetes in Youth Study. Peripheral Neuropathy in the SEARCH for Diabetes in Youth Cohort: A Pilot Study. Diabetes 2012; 61 (Supplement 1):564-A144.
69. **Pop-Busui R**, Martin CL, Bell RA, Lauer A, Divers J, Dabelea D, Pettitt DJ, Saydah S, Linder B, Pihoker C, Standiford DS, Rodriguez BL, Feldman EL, For the SEARCH for Diabetes in Youth Study Group. Cardiovascular Autonomic Neuropathy in the SEARCH for Diabetes in Youth Cohort: A Pilot Study. Diabetes 2012; 61 (Supplement 1):573-A146.
70. **Pop-Busui R**, Lu J, Perkins BA, Albert S, Escobedo J, Green J, Palumbo P, Whitehouse F, Jones TZ. Impact of Glycemic Control Strategies on the Incidence of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes 2012;61 (Supplement 1):63-A18
71. Shtein R, Raval N, Hussain M, Ryan K, Martin C, Lentz SI, and **Pop-Busui R** : In vivo confocal evaluation of the corneas in patients with diabetes mellitus. Abstract Book: P37: 128, the 22nd Annual NEURODIAB Meeting, Dresden Germany.
72. **Pop-Busui R**, Lu J, Perkins BA, Albert S, Escobedo J, Green J, Palumbo P, Whitehouse F, Jones TZ. Impact of Glycemic Control Strategies on the Incidence of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Abstract Book: O7: 27, the 22nd Annual NEURODIAB Meeting, Dresden Germany.

73. Feldman EL, Martin CL, Bell RA, Lauer A, Divers J, Dabelea D, Pettitt DJ, Saydah S, Linder B, Pihoker C, Standiford DS, Rodriguez BL, **and Pop-Busui R**, for the SEARCH for Diabetes in Youth Study. Peripheral Neuropathy in the SEARCH for Diabetes in Youth Cohort: A Pilot Study. Abstract Book: O: 58, the 22nd Annual NEURODIAB Meeting, Dresden Germany.
74. **Pop-Busui R**, Martin CL, Bell RA, Lauer A, Divers J, Dabelea D, Pettitt DJ, Saydah S, Linder B, Pihoker C, Standiford DS, Rodriguez BL, Feldman EL, For the SEARCH for Diabetes in Youth Study Group. Cardiovascular Autonomic Neuropathy in the SEARCH for Diabetes in Youth Cohort: A Pilot Study. A Pilot Study. Abstract Book: P21: 107, the 22nd Annual NEURODIAB Meeting, Dresden Germany.
75. McKeon K, Brown M, **Pop-Busui R**: Association between Impaired Cardiovascular Autonomic Function and Hypoglycemia in Patients with Type 1 Diabetes Mellitus. Circulation, 2012, A:16079.
76. **Pop-Busui R**, Sarma A, Braffett BH, Hotaling J, Cleary PA, Martin CL, Dunn R, Wessells H and the DCCT/EDIC Research Group. Cardiovascular Autonomic Neuropathy and Erectile Dysfunction in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Diabetes 2013, 62: Supplement 1, 51O-A 13.
77. Jaiswal M, Plunkett C, Nelson P, Henderson J, Comment N and **Pop-Busui R**. Glycemic Variability but not Glycemic Exposure Predicts Lower Heart Rate Variability in Patients with type 1 diabetes. Diabetes 2013, 62: Supplement 1, 175O-A 45.
78. Hur J, Sullivan KA, Callaghan B, **Pop-Busui R**, Feldman EL. Identification of Factors Associated with Sural Nerve Regeneration and Degeneration in Diabetic Neuropathy. Diabetes 2013, 62: Supplement 1, 578 P-A 146.
79. Hotaling JM, Sarma A, **Pop-Busui R**, Cleary P, Dunn R, Wessells H. Autonomic Neuropathy, Sexual Dysfunction and Urinary Incontinence in Women with Type 1 Diabetes: Findings from the DCCT/EDIC. Diabetologia 2013, 56: Supplement 1, S1-S566
80. **Pop-Busui R**, Hotaling JM, Wessells H, Braffett B, Cleary P, Dunn R, Martin C, Sarma A. Cardiovascular Autonomic Neuropathy and Lower Urinary Tract Symptoms in Men with Type 1 Diabetes. Diabetologia 2013, 56: Supplement 1, S1-S566.
81. **Pop-Busui R**, Sarma A, Braffett B, Hotaling J, Cleary P, Martin C, Dunn R, Wessells H and the DCCT/EDIC Research Group. Cardiovascular Autonomic Neuropathy and Erectile Dysfunction in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Abstract Book: P19: O2, the 23rd Annual NEURODIAB Meeting, Barcelona, Spain.

82. Hur J, Sullivan K, Callaghan BC, **Pop-Busui R**, Feldman EL. Identification Of Factors Associated with Sural Nerve Regeneration and Degeneration in Diabetic Neuropathy. Abstract Book: P25: O8, the 23nd Annual NEURODIAB Meeting, Barcelona, Spain.
83. Jaiswal M, Martin CL, Brown MB, Albers J, Callaghan B, Feldman EL, and **Pop-Busui R**. Effects of Exenatide on Measures of Diabetic Peripheral Neuropathy in Subjects with Type 2 Diabetes: Proof of Concept, Open Label, Randomized Trial. Abstract Book: P81:P16, the 23nd Annual NEURODIAB Meeting, Barcelona, Spain.
84. Wrobel J, Peethambaran A, Le T, Luring C, Wensman J, Grewal G, Najafi B, and **Pop-Busui R**. A Novel Shear-Reduction Insole Effect on Thermal Response to Walking Stress, Balance and Gait. Diabetes 2014, 63: Supplement 1, 217-OR, A-57.
85. Jaiswal M, Divers J, Isom S, Urbina E, Dolan L, Imperatore G, Linder B, Bell R, Liese A, Dabelea, D, Pettitt D, Pihoker C, Marcovina S, Martin CL, Feldman EL and **Pop-Busui R**: Prevalence and Risk Factors of Cardiovascular Autonomic Neuropathy among Youth with Type 1 Diabetes: SEARCH Cohort Study; Diabetes 2014, 63: Supplement 1, 566-P, A-145.
86. **Pop-Busui R**, Braffett B, Hotaling J, Cleary P, Martin CL, Dunn R, Wessells H, Sarma A: Diabetic Neuropathy and Urologic Complications in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Diabetes 2014, 63: Supplement 1, 576-P, A-148.
87. Jaiswal M, Martin CL, Feldman EL and **Pop-Busui R**: Effects of Exenatide on Measures of Small Fiber Neuropathy in Patients with Type 2 Diabetes. Diabetes 2014, 63: Supplement 1, 580-P, A-149.
88. Jaiswal M, Divers J, Isom S, Martin CL, Liese A , Dolan L, Dabelea D, Pettitt D, Pihoker C, Marcovina S, Saydah S, Linder B, Bell R, **Pop-Busui R**, Feldman EL: Prevalence and Clinical Correlates of Diabetic Peripheral Neuropathy among Youth with Type 1 Diabetes: SEARCH for Diabetes in Youth Cohort Study. Diabetes 2014, 63: Supplement 1, 579-P, A-148.
89. **Pop-Busui R**, Braffett B, Hotaling J, Cleary P, Martin CL, Dunn R, Wessells H, Sarma A: Diabetic Neuropathy and Urologic Complications in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Abstract Book: O-23:P27, the 24th Annual NEURODIAB Meeting, Sopron, Hungary.
90. **Pop-Busui R**, Braffett B, Hotaling J, Cleary P, Martin CL, Dunn R, Wessells H, Sarma A: Diabetic Neuropathy and Urologic Complications in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study (DCCT/EDIC). Diabetologia 2014, Vol 57, Supplement 1, 127.
91. Ang L, Jaiswal M and **Pop-Busui R**. Measures of Cardiovascular Autonomic Neuropathy and Sudomotor Dysfunction in Patients with Type 1 Diabetes (T1D), Endocrine Society.

92. Sarma AV, **Pop-Busui R**, Braffett BH, Cleary P, Bebu I, Arends V, Steffes M, Feldman EL, Wessells H, Low PA, Orchard TJ, Kim C, DCCT/EDIC Research Group: Testosterone (T) and Cardiac Autonomic Neuropathy (CAN) in Men with Type I Diabetes (T1D): The Epidemiology of Diabetes Interventions and Complications Study (EDIC). Diabetes 2015, 64, Supplement 1, 2733-PO, A689.
93. Jaiswal M, Fufaa, G, Martin CL, **Pop-Busui R**, Nelson RG, Feldman E: Burden of Diabetic Peripheral Neuropathy among Pima Indians. Diabetes 2015, 64, Supplement 1, 658-P, A167.
94. Jaiswal M, Martin CL, Sippl RM, Duca LM, Feldman EL, **Pop-Busui R**, Snell-Bergeon JK: Cardiovascular Autonomic Neuropathy and Coronary Artery Calcium in Type 1 Diabetes: The CACTI Study. Diabetes 2015, 64, Supplement 1, 638-P, A163.
95. Ang L, Jaiswal M, Plunkett B, **Pop-Busui R**: Longitudinal Changes of Sudomotor Function in Type 1 Diabetes. Diabetes 2015, 64, Supplement 1, 644-P, A164.
96. Wheelock KM, Jaiswal M, Martin CL, Fufaa GD, Weil JE, Feldman EL, Nelson RG, **Pop-Busui R**: Cardiovascular Autonomic Neuropathy in Pima Indians with Diabetic Kidney Disease (DKD). Diabetes 2015, 64 Supplement 1, 588-P, A150.
97. Wheelock KM, Jaiswal M, Martin CL, Fufaa GD, Weil JE, Feldman EL, Nelson RG **and Pop-Busui R**: Cardiovascular Autonomic Neuropathy in Pima Indians with Diabetic Kidney Disease (DKD) Diabetologia 2015, Vol.58, Suppl.1: S504.
98. Ang L, Jaiswal M, Plunkett B, **and Pop-Busui R**: Longitudinal Changes of Sudomotor Function in Type 1 Diabetes. Abstract Book: P1-58, the 25th Annual NEURODIAB Meeting, Elsinore, Denmark.
99. Wheelock KM, Jaiswal M, Martin CL, Fufaa GD, Weil JE, Feldman EL, Nelson RG **and Pop-Busui R**: Cardiovascular Autonomic Neuropathy in Pima Indians with Diabetic Kidney Disease (DKD) Abstract Book: O36-54, the 25th Annual NEURODIAB Meeting, Elsinore, Denmark.
100. Jaiswal M, Plunkett B, **and Pop-Busui R**: Blood Pressure Variability in Subjects with Type 1 Diabetes. Abstract Book: P25-82, the 25th Annual NEURODIAB Meeting, Elsinore, Denmark.